PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 1
A PHASE 2A, RANDOMIZED, DOUBLE BLIND (SPONSOR-OPEN), PLACEBO 
CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE 
PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF PF-05221304 AND 
PF-06865571 CO-ADMINISTERED FOR 6 WEEKS IN ADULTS WITH 
NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
Investigational Product Number: PF-05221304 and PF-06865571
Investigational Product Name: Not Applicable
United States (US) Investigational New 
Drug (IND) Number:
Protocol Number: C3711001
Phase: 2aCCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 2Document History
Document Version Date Summary of Changes and Rationale
Amendment 1 02 October 2018 This amendment is making the following substantial 
changes as requested b y the United States Food and
Drug Administration (US FDA) as part of their 
review of the O riginal protocol submitted on 
15August 2018.
1.In response to agency ’s request to re move the 
term “m etabolic s yndrome ” from Inclusion 
Criteri on #5 (Section 4.1), the text was modified 
to reflect that the 2 out of 5 criteria listed should 
be met; the criteria being 
“commonly  associated ”
with metabolic sy ndrome instead of original text, 
which reflected that 5 criteria may be indicative 
of metabolic s yndrome.
2.In response to agency ’s request to add trial 
stopping criteria, an additional sub- section was 
added in Study  Design ie ,
Section 3.3: 
“Considerations for Pausing or Stopping 
Treatment A rm 
or Trial Based on Observed 
Safety ”. The sub -section outlines the rules for 
pausing or stopping a treatment arm or Trial .
Modifications in text were also made in related 
Section 9.8.
3.In response to agency ’s request to establish 
baseline values for live r enzy mes by  at least two 
samples obtained at least 4 weeks apart to 
account for disease related changes in liver 
enzy mes and bilirubin, t ext was added to the 
Exclusion Criteri on
#2 (Section 4.2 ) to clarify  
that subjects meeting the exclusion criteri on for
liver enzy mes and bilirubin laboratory  values in 
either Visit 1 or Visit 4will be excluded from the 
study . The stud y design Figure 1: C3711001 
Study  Design was revised 
to reflect that the time 
duration between Screen 1 (Visit 1) and Visit 4 
(start of Run- In) is expected to be at least 
4weeks ,but not to exceed 6 weeks , thereby , 
fulfilling a minimum 4week time period 
requirement between 2 visits .Schedule of 
Activities and t ext in Section 3.1and Section 6.1

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 3was modified to reflect changes to Figure 
schematic. 
In addition to the FDA requested changes, following 
revisions have been made to the protocol in this 
Amendment : 
4.Schedule of Activities:
In Table 1, text in column header “Treatment 
Phase” was modified to include the 
phrase “ …. unless otherwise noted” to 
accommodate post -dose PK collections which 
will be conducted 2hours post dosing . 
5.Schedule of Activities:
For Visit 10, instead of allowed 2days from 
Day 42 visit, the allowable window has been 
changed to 
‘42(-3) ’ ie,subjects are allowed to 
make Visit 10 up to 3 days in advance of Day 42 
visit, but not bey ond Day 42. This change was 
made to ensure to limit potential medication 
errors of dosing bey ond 42 days specified by  the 
protocol . Additional footnote “b” was added to 
clarify  the visit wi ndow.
6.Schedule of Activities
, Section 5.4.2, and 
Section 5.5:
Text was added in foot note “ k”of Table 1, in 
Section
5.4.2 and Section 5.5 to clarify  that on 
Visit 10, there will not be an yevening dose.
7. Section 1.4.2
Text was modified to clarify the lang uage 
regarding pote ntial effect of PF -06865571 in
inhibit
ingOCT2/MATE.
8. Section 1.5.1: 
Atypographical error was made in the dose 
rationale text
. The error was rectified as below:
“The anticipated exposures of PF- 05221304 at 
15mg BID in this study  are 122- fold and 29- fold 

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 4higher lower (C maxand AUC 24, respectively) than 
the NOAEL (30 mg/kg (QD) PF-05221304 + 300 mg/kg (BID) PF-0686557) in the 6-week combination toxicology study in monkeys.  Similarly, the anticipated exposures of PF-06865571 at 300 mg BID in this study are 3.7 and 6.2-fold higher 
lower than the 6-week 
monkey NOAEL.”
 
 
 
 
 
 
10. Section 1.5.2:
Under heading ‘Clinical Experience with 
Combination of PF-05221304 and PF-06865571’, a brief summary was added regarding trends of fasting triglyceride levels observed in C3711002 Cohort 2. This summary was unintentionally excluded in the original version.
11. Section 4.1, Inclusion Criterion #6:
Divided text from a single inclusion criterion
(#6 in Original Protocol) into 2 individual inclusion criteria. Instead of Inclusion Criterion #6 in the Original protocol which stated that “At Screen 1 and Screen 2 both
….” Inclusion 
Criterion #6 in this Amendment states “At Screen 1…”. In addition, Criterion #7 has been added which states “At Screen 2…”. This change was made to properly capture protocol deviations associated with each criterion in the eCRFs(electronic case report forms).
12. Section 4.2, Exclusion criterion #3:
Language modified to clarify that subject has to 
be negative for urine drug test at Screen 1 (Visit 1), start of Run-in (Visit 4) and at Baseline CCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 5(Visit 6)visit in order to enroll and remain in the 
study , not just Screen 1 (Visit 1) as implied in the 
Original Protocol .
13.
Section 6.4.4 and Footnote “g” in Schedule of 
Activities
Added text to clarify  that if MRI -PDFF 
assessment for Visit 10 is completed on the day of 
the site visit for Visit 10, subjects should refrain 
from taking IP until blood dra w for laboratory  
assessments is com pleted.   
Original 
protocol09 August 2018 Not applicable ( N/A)
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and institutional review boards (I RBs)/ethics committees 
(ECs).

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 6TABL E OF CONTENTS
LIST OF TABLES ...................................................................................................................10
LIST OF FIGURES .................................................................................................................11
APPENDI CES .........................................................................................................................11
SCHEDUL E OF ACTIVITI ES................................................................................................12
1. INTRODUCTION ...............................................................................................................15
1.1. Mechanism of Action /Indication .............................................................................16
1.2. Background and Rationale
......................................................................................16
1.3. Background Information for PF -
05221304.............................................................17
1.3.1. Nonclinical Experience with PF -
05221304................................................17
1.3.2. Clinical Experience with PF
-05221304......................................................18
1.4. Background Information for PF -
06865571.............................................................20
1.4.1. Nonclinical Experience with PF -
06865571................................................20
1.4.2. Clinical Experience with PF-
06865571......................................................20
1.5. Background Information on PF -05221304 and PF -06865571 Combination ..........23
1.5.1. Non
-Clinical Experience with Combination of PF -05221304 and 
PF-06865571....................................................................................................23
1.5.2. Clinical Experience with Combination of PF
-05221304 and 
PF-06865571....................................................................................................24
1.6. S tudy Rationale .......................................................................................................27
1.6.1. Design Rationale
.........................................................................................28
1.6.2. Rationale for Population Enrolled ..............................................................29
1.6.3. Dose Rationale ............................................................................................30
1.6.4. Rationale for Banked Biospecimen Collection
...........................................31
2. STUDY OBJECTIVES AND ENDPOINTS .......................................................................31
3. STUDY DESIGN ................................ ................................ ................................ ................. 33
3.1. Study  Overview .......................................................................................................33
3.2. Stop
ping Rules in I ndividual Subjects ....................................................................34
3.3. Considerations for Pausing or Stopping Treatment Arm or Trial Based on 
Observed Safet y.........................................................................................................35
4. SUBJECT ELIGIBILI TY CRI TERIA .................................................................................35
4.1. I nclusion Criteria .....................................................................................................35
4.2. Exclusion Criteria ....................................................................................................37

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 74.3. Randomization Criteria ...........................................................................................41
4.4. L ifesty le Requirements ...........................................................................................41
4.4.1. Meals and Dietary  Restrictions ...................................................................41
4.4.2. Alcohol, Caffeine, and Tobacco .................................................................41
4.4.3. Phy
sical Activity .........................................................................................42
4.4.4. Contraception ..............................................................................................42
4.5. Sponsor’s Qualified Medical Personnel ..................................................................43
5. STUDY TREATMENTS .....................................................................................................43
5.1. Allocation to Treatment
..........................................................................................44
5.2. Breaking the Blind ..................................................................................................45
5.3. Subject Compliance .................................................................................................45
5.4. I nvestigational Product Supplies .............................................................................45
5.4.1. Dosage Form(s) and Packaging ..................................................................45
5.4.2. Preparation and Dispensing ........................................................................45
5.5. Administration .........................................................................................................46
5.6. I nvestigational Product Storage ..............................................................................46
5.7. I nvestigational Product Accountabilit y
...................................................................47
5.7.1. Destruction of Investigational Product Supplies
........................................47
5.8. Concomitant Treatment(s) .......................................................................................48
5.8.1. Medications for Glycemic Control .............................................................48
5.8.2. Anti
-Hypertensive Me dications ..................................................................48
5.8.3. L
ipid-Modify ing Medications ....................................................................49
5.8.4. Other Acceptable Concomitant Medications ..............................................49
5.8.5. Prohibited Concomitant Medications
.........................................................50
5.9. Rescue Medication ..................................................................................................51
6. STUDY PROCEDURES
................................ ................................ ................................ .....51
6.1. Screening .................................................................................................................51
6.2. Run
-in Period (Visit 4) ............................................................................................52
6.3. Basel ine MRI -PDFF (Visit 5) .................................................................................53
6.4. Study  Period ............................................................................................................53
6.4.1. Day  1 (Visit 6) ................................ ................................ ............................ 53
6.4.2. Day  5 (Visit 7) ................................ ................................ ............................ 53

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 86.4.3. Day 14 (Visit 8) and Day 28 (Visit 9) ................... .....................................54
6.4.4. Day 42 (Visit 10) ....................................... .................................................54
6.4.5. Follow-up............................................... .....................................................54
6.4.6. Follow-up Contact ....................................... ...............................................55
6.5. Subject Withdrawal/Early Termination ...................... ............................................55
7. ASSESSMENTS................................................. ............................................................... ..56
7.1. Imaging Assessments ....................................... .......................................................57
7.1.2. Assessment of Liver Fat Using MRI-PDFF Acquisition and A nalysis......57
7.1.3. Analysis of MRI-PDFF Images Including Determination of 
Eligibility .................................................... .....................................................58
7.2. Safety.................................................... ............................................................... ....59
7.2.1. Physical Examinations................................... .............................................59
7.2.2. Body Weight and Hula-hoop Test .......................... ....................................59
7.2.3. Blood Pressure and Pulse Rate ........................... ........................................60
7.2.4. Electrocardiogram....................................... ................................................60
7.3. Clinical Laborat ory Tests ................................. .......................................................61
7.3.1. Serum for Cystatin C .................................... ..............................................62
7.5. Pharmacodynamics Parameters............................... ................................................64
7.5.1. Serum for Lipid Panel................................... ..............................................65
7.5.3. Apolipoprotein A1, B100 and Apolipoprotein C3 ........... ..........................65
7.5.8. Plasma PCSK9............................................ ................................................66
7.6. Pharmacogenomics.......................................... ........................................................66CCI
CCI
CCI
CCI
CCI
CCI
CCIC
C
PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 97.6.1. Genotyping Analysis ..................................... .............................................66
7.7. Banked Biospecimens ....................................... ......................................................66
7.7.1. Additional Research..................................... ...............................................67
8. ADVERSE EVENT REPORTING..................................... .................................................68
8.1. Requirements.............................................. .............................................................68
8.1.1. Additional Details On Recording Adverse Events on the CR F..................69
8.1.2. Eliciting Adverse Event Information..................... .....................................69
8.1.3. Withdrawal From the Study Due to Adverse Events (See als o the 
Subject Withdrawal 6.5) ........................................ ..........................................69
8.1.4. Time Period for Collecting AE/SAE Information........... ...........................70
8.1.5. Causality Assessment .................................... .............................................70
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authoriti es ..................71
8.2. Definitions............................................... ............................................................... .71
8.2.1. Adverse Events .......................................... .................................................71
8.2.2. Abnormal Test Findings .................................. ...........................................72
8.2.3. Serious Adverse Events .................................. ............................................72
8.2.4. Hospitalization......................................... ...................................................73
8.3. Severity Assessment....................................... .........................................................74
8.4. Special Situations ........................................ ............................................................74
8.4.1. Protocol-Specified Serious Adverse Events ............... ................................74
8.4.2. Potential Cases of Drug-Induced Liver Injury............ ................................74
8.4.3. Exposure to the Investigational Product During Pregnancy  or 
Breastfeeding, and Occupational Exposure ....................... ..............................76
8.4.4. Medication Errors ....................................... ................................................78
9. DATA ANALYSIS/STATISTICAL METHODS........................... ....................................79
9.1. Sample Size Determination................................. ....................................................79
9.2. Analysis of the Primary Endpoint .......................... .................................................79
9.3. Analysis of Secondary Endpoints ........................... ................................................80
9.4. Analysis of Tertiary/Exploratory Endpoints ................ ...........................................80
9.6. Analysis of Other Endpoints ............................... ....................................................80
9.7. Safety Ana lysis........................................... .............................................................80CCI
CCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 109.8. I nterim Anal ysis......................................................................................................81
9.9. Data Monitoring Committee ...................................................................................81
10. QUALITY CONTROL  AND QUALITY ASSURANCE .................................................82
11. DATA HANDLING AN
D RECORD KEEPING .............................................................82
11.1. Case Report Forms/Electronic Data Reco rd.........................................................82
11.2. Record Retention ...................................................................................................83
12. ETHI CS..............................................................................................................................83
12.1. I nstitutiona l Review Board/Ethics Committee ......................................................83
12.2. Ethical Conduct of the Study ................................................................................84
12.3. Subject I nformation and Consent ..........................................................................84
12.4. Reporting of Safet y Issues and Serious Breaches of the Protocol or ICH 
GCP ...........................................................................................................................85
13. DEFINITION OF EN D OF TRIAL ...................................................................................85
13.1. End of Trial in All Participating Countries ...........................................................85
14. SPONSOR DI SCONTI NUATION CRITERIA ................................................................85
15. PUBLICATION OF S TUDY RESUL TS..........................................................................85
15.1. Communication of Results by  Pfizer ....................................................................85
15.2. Publications by  Investigators ................................................................................86
16. REFERENCES ..................................................................................................................88
LIST OF TABLES
Table 1. Schedule of Activities ...........................................................................................12
Table 2. Summary  of Plasma PF -06865571 PK Parameters Following Single Oral 
Doses in C2541001
...............................................................................................21
Table 3. Summary  of Preliminary  Steady  State (Day  14) Plasma PF -
068655 71 PK 
Parameters Following Multiple Oral Doses in C2541002 ................................ ....22
Table 4. PF-05221304 PK Parameters following Administration of PF -05221304 
Alone (15 mg BID) or with PF -06865571 (300 mg BID) in C 3711002 ..............27
Table 5. PF-06865571 PK Parameters following Administration of PF -
06865571 
Alone (300 mg BID) or with PF 05221304 (15 mg BID) in C3711002...............27
Table 6. Study  Treatment Regimen and Dispensing Schedule ................................ ........... 44
Table 7. Clinical L aboratory  Tests .....................................................................................61

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 11LIST OF FIGURES
Figure 1. C3711001 Study  Design .......................................................................................33
APPENDICES
Appendix 1. Abbreviations ......................................................................................................90
Appendix 2. Strong CYP3A Inhibitors and Inducers*
............................................................95
Appendix 3. Guidance to I nvestigators –Management of Individual Subjects With 
Decrease in Platelet Count ....................................................................................96
Appendix 4. Guidance to I nvestigators –Management of Individual Subjects With 
Elevation in Fasting Serum Trigl ycerides ............................................................97

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 12SCHEDULE OF ACTIVITIES
The schedule of activities table below provides an overview of the protocol visits and procedures.  Refer to Section 7 of the protocol 
for detailed information on each procedure and assessment requi red for compliance with the protocol.  The investigator may sch edule 
visits (unplanned visits) in addition to those listed on the sc hedule of activities table, in order to conduct evaluations or a ssessments 
required to protect the well-being of the subject.
Table 1. Schedule of Activities
Visit IdentifierScreen 1 Screen 2 Screen 3 Run-In BaselineaTreatment Phase [all procedures before
morning dose of blinded IP, unless 
otherwise noted]Follow-up
Early
Termi
nation 
(ET)Week Relative to Dosing on Day 1Visit 1 to Visit 4 should be 
≥≥4 and ≤6 weeks-2 -1 0 1 2 4 6 7-14 days 
post last 
dose28-35 
days post 
last dosec Days Relative to Dosing on Day 1 -14±2 -4±2 1 5±1 14±2 28±242(-3)b
Visit to Site or Imaging Facility 1 2 3 4 5 6 7 8 9 10 11 --
Informed consent & demography X
Medical history X
Medication history (update)dXX X X X X X X X X
 FibroScan®)eXX X X X X
Liver fat (via MRI-PDFF)e,fXX XgXh
Physical examination (PE)iXX X X X X
Body weight (+ hula-hoop test at Screen 1 only) XX X X X X
Single, supine 12-lead ECG XX X X X X X X X
Single, seated vitals assessment (BP & pulse rate) XX X X X X X X X
Serious and non-serious adverse event (AE) 
monitoringX →→ → → → → → → →→ XX
Randomization in trial (via IRT) X
Dispense Investigational Product (IP) (via IRT)jXX X X
Administration of IPkX→ X X XX X
Compliance via pill count of returned IP XX X X X X
Confirm contraceptive method XX X X X X X X
Instructions on Dosing of IP XX X X X
Counseling on diet/exercise guidelines XX X X X X
Blood Collections after ≥8-hour, preferably 10-hour fast; refer to Table 7 for additional details
Clinical laboratory tests XX X X X X X X X
Cystatin ClXX X X X X X X XCCI
PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 13Visit IdentifierScreen 1 Screen 2 Screen 3 Run-In BaselineaTreatment Phase [all procedures before
morning dose of blinded IP, unless 
otherwise noted]Follow-up
Early
Termi
nation 
(ET)Week Relative to Dosing on Day 1Visit 1 to Visit 4 should be 
≥≥4 and ≤6 weeks-2 -1 0 1 2 4 6 7-14 days 
post last 
dose28-35 
days post 
last dosec Days Relative to Dosing on Day 1 -14±2 -4±2 1 5±1 14±2 28±242(-3)b
Visit to Site or Imaging Facility 1 2 3 4 5 6 7 8 9 10 11 --
Serology (HepBsAg, HepBcAb, HCVAb, HCV RNA, 
HIV), Serum FSH (females only)X
Ceruloplasmin, Coagulation (aPTT, PT, PT/INR), 
α1-antitrypsin (A1AT)X
 
Fasting Lipid Panel XX X X X X X X X
 
Apolipoproteins (A1, B100 and C3) XX
Plasma PCSK9 XX
OATP Pharmacogenomics blood sampleoX
Banked bio-specimen: Prep D1.5oX
Banked bio-specimen: Prep B1.5 and B2.5 XX
Urine Collections
Urine drug testpXX X
Urinalysis (and microscopy, as appropriate) XX X X X X X X X
Abbreviations: →= ongoing/continuous event; A1AT = α1-antitrypsin; AE = Adverse Event; aPTT = activated Partial Thr omboplastin Time; BP = Blood Pressure; 
 ECG = electrocardiogram; ET = Early Termination; FSH = Follicl e Stimulating Hormone;  
HCVAb = Hepatitis C Virus Antibody; HCV RNA = Hepatitis C Virus Ri bonucleic Acid; HepBcAb = Hepatitis B Core Antibody; HepBsAg = Hepatitis B Surface Antigen; 
HIV = Human Immunodeficiency Virus; ; IP = Investigational Produc t; IRT = Interactive Response Technology; 
MRI-PDFF = Magnetic Res onance Imaging – Proton Density Fat Fractio n; OATP = Organic Anion Transporter Polypeptide; PCSK9 = Proprot ein Convertase Subtilisin/kexin 
type 9; PE = Physical Examination; ;  PT = Prothrombin Time; 
PT/INR = Prothrombin Time/International Normalized Ratio
a. baseline for liver fat assessments by MRI-PDFF is Day -4 ±2; baseline for all other assessments is Day 1, prior to first do se.
b. The Day 42 visit can occur up to 3 days prior ie, Day 39 to Day 42 , but no later than Day 42. CCI CCI
CCI
CCI CCICCI
CCI
CCI
PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 14c. To occur via telephone contact and must occur within 28-35 days  from administration of the final dose of double-blind IP; this  contact can be considered as on-site in order to 
permit follow-up of open AEs and/or abnormal laboratory tests f rom prior visit(s), as needed.
d. Update at post-screening visits.
e. Assessment to be performed following ≥4-hr fast, at site (as part of site visit) or separate visit(s)  to Imaging facility; attempts to be made to perform baseline v isit for each 
assessment (Visit 6 for FibroScan®and Visit 5 for MRI-PDFF) within ±2-hr window of initial screen time (Visit 1 for FibroScan®and Visit 3 for MRI-PDFF).  
Post-randomization assessments should be within ±2-hr window of baseline visit time (Visit 6 for FibroScan®and Visit 5 for MRI-PDFF).
f. A single repeat assessment is permitted at screening as deter mined by sponsor-identified central imaging vendor; at baseline  (Visit 5) and at Visit 10, single repeat is 
permitted only after consultation with the Sponsor.
g. MRI-PDFF assessment to be performed within approximately 24 ho urs prior to Visit 10, or on the same day as Visit 10. If subjects  perform MRI-PDFF in the morning of 
same day as Visit 10 visit, they should wait for blood collectio ns before administration of morning dose at the site. Subjects w ill not take evening dose on Day 42. 
h. MRI-PDFF will be obtained only for those subjects who receive  at least 4 weeks of double-blind IP ie for subjects who drop out  after Visit 9.  
i. Includes arm and waist circumference, and height at Visit 1 onl y; targeted PE at Visit 4, Visit 6, Visit 10, Visit 11 and Early Term ination; limited PE for follow-up on open 
AEs/abnormal tests, at investigator discretion.
j. Visit 4 and Visit 5 reflect single-blind placebo regimen; from Vi sit 6 onwards, reflects double-blind randomized regimen.
k. Administration of single or double-blind IP is twice daily ; administration of witnessed dosing at site is on the mornings of Visit 4 for single-blind IP and on the mornings of 
Visit 6, Visit 7, Visit 8, Visit 9, and Visit 10 for double-blind IP , with meal.  On these visits, evening dose to be administered as outpatient, with evening meal, except for 
Visit 10 for which, subjects will not take evening dose.
l. Review of Cystatin C results not required for dosing or discha rge.
o. If not collected on the designated collection day, collect at  the next available time point when bio-specimens are being col lected in conjunction with a subject visit.
p. A dipstick, provided by Sponsor-identified central lab, will be used.CCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 151. INTRODUCTION
The dual acet yl-CoA (coenzy meA) carboxy lase1 and 2 ( ACC1/2 )inhibitor PF -05221304 
and the diacy lglycerol acy ltransferase 2 (DGAT2) inhibitor PF-06865571 are each currentl y 
in clinical development as monotherap y agents for the treatment of non-alcoholic 
steatohepatitis ( NASH )with liver fibrosis.  Nevertheless, as exemplified by other metabolic 
disorders (eg, t ype2 diabetes, dy slipidemias, etc), it is pos
sible that a single drug may be 
insufficient to successfully treat NASH and therefore, combination therapy is being 
considered as an earl y intervention strategy.   Inhibition of ACC1/2 by  PF-05221304 and 
inhibition of DGAT2 by  PF-06865571 are anticipated to modulate lipid metabolism in 
distinct and complementary  way s, suggesting that co- administration of the two 
investigational agents may lead to greater efficacy  than either agent administered alone.
PF-05221304 is a potent, selective, orally  bioavailable, a nd reversible dual acet yl-CoA 
(coenzy meA) carbox ylase1 and 2 (ACC1/2) inhibitor (ACCi) designed to have as ymmetric 
distribution to the liver, with 100fold asy mmetric hepatic distribution demonstrated in both 
rats and monkey s.  ACC inhibition stimulates fatty acid oxidation, suppresses hepatic 
denovo lipogenesis (DNL), and reduces steatosis in animal models1and in humans.2  As a 
result of its asy mmetric distributi on favoring the liver ,PF-05221304 is expected to inhibit 
DNL and stimulate fatt y acid oxidation in the liver to a greater extent than in peripheral 
tissues.
  In humans, administration of PF -05221304 has been shown to suppress hepatic DNL 
in a Phase 1 stud y in healthy  adult subjects.  This inhibition of hepatic DNL is postulated to 
result in a decrease and normalization of the excessive DNL observed in non -alcoholic fatty  
liver disease (NAFLD), and consequentl y reduce fat accumulation in the liver.  Emergin g 
data also suggest that suppression of DNL through reduction in ACC activity  restrains the 
formation of the inflammatory  interleukin -17 secreting T cells of the T helper 17 lineage 
(Th17) cells which in turn promotes the development of anti- inflammatory  Foxp3(+) 
regulatory  T(Treg) cells.3  Based on these observations, it is hy pothesized that ACC1/2 
inhibition by  PF-05221304 may lead concurrently to reductions in liver fat content and
anti-inflammatory  effects ,thus mitigating two key  pathophy siologic drivers of NAFLD. 
PF-06865571 is an oral, small molecule diacy lglycerol acy ltransferase 2 (DGAT2) inhibitor 
that is postulated to decrease hepatic trigl yceride (TG) s ynthesis and hepatic lipid burden in 
NAFLD and N ASH.  Diacy lglycerol acy ltransferases (DGATs) catal yze the terminal step in 
TG sy nthesis; specifically , the esterification of a fatty  acid with diacy lglycerol (DAG) 
resulting in the formation of TG.4  In mammals, two structurally  unrelated DGAT enz ymes 
(DGAT1 and DGAT2) have been characterized.  DGAT1 is highl y expressed in the intestine 
and play s a central role in fat absorption.5  DGAT2 is highly expressed in the liv er and 
adipose tissue .6  In preclinical models, blockade of hepatic DGAT2 using antisense 
oligonucleotides results in both down -regulation of the expression of multiple genes 
encoding proteins involved in lipoge nesis and parallel induction in oxidative pathway s.7,8  
Thenet result of these changes is a decrease in the levels of hepatic DAG and TG lipid 
which, in turn, reduce s hepatocy te lipid burden and decreases hepatic very  low density  
lipoprotein (VLDL) TG secretion.8,9

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 16The purpose of this stud y is to assess if the liver fat lowering effect of co -administration of 
PF-05221304 and PF- 06865571 is greater than the effect of PF-05221304 or PF -06865571, 
when administered alone.   The study  will also assess the safet y and tolerability  of 
co-administration of PF-05221304 and PF- 06865571 and ef fects on selected 
pharmacod ynamics/ exploratory  parameters eg trigl ycerides , in subjects with NAFLD. 
1.1. Mechanism of Action/ Indication
PF-05221304 is a potent, selective, orally  bioavailable, and reversible dual ACC1/2 small 
molecule inhibitor, designed to ha ve as ymmetric distribution to the liver.  It is being 
developed for the treatment of NASH with fibrosis.
PF-06865571 is an oral, small molecule DGAT2 inhibitor that is currently  being developed 
for the treatment of NASH
with fibrosis.
1.2.Background and Ration ale
The World Health Organization lists NAFLD and NASH as the most important conditions 
contributing to the global health burden due to liver diseases, with NASH acknowledged as a 
potentially  fatal condition leading to cirrhosis, liver failure, and hepatoc ellular carcinoma 
(HCC).10NASH is a clinical and histological subset of NAFLD (defined as presence of 
5%hepatic steatosis in the absence of other liver disease etiologies ) that is associated with 
increased a ll-cause mortality , cirrhosis and end-stage liver disease, increased cardiovascular 
mortality , and increased incidence of both liver related and non -liver related cancers.11  It is 
diagnosed clinicall y by liver biopsy  demonstrating steatosis, inflammation, and cy tological 
ballooning of liver hepatocy tes, often with vary ing degrees of fibrosis.  NASH progresses 
with increasing severity  of fibrosis, with cirrhosis developing in a subset of patients11and a
common complication of cirrhosis being HCC
.12
In a recent meta -analysis, the global prevalence of NAFLD was estimated at 25%, with the 
prevalence of NASH in the subset with biopsy -proven NAFLD assessed at 59%.13  The 
majority  of the population with NAFLD has simple steatosis which has, in general, a benign 
clinical course.  A proportion of patients with NAFLD progress to having hep atocellular 
ballooning and lobular inflammation 
– taking close to a decade to progress from 1 stage to 
the next and 30 -40years to develop cirrhosis; however, a smaller subset of patients progress 
very rapidly (within 10 years) to liver cirrhosis from NAFL D.14  Patients with NASH may  be 
asymptomatic or have non -specific s ymptoms such as fatigue, despite having significant 
disease on liver biops y and associated risk for progression to cirrhosis and liver -
related 
mortality .  The 5 -year (67%) and 10- year (38%) survival rates in patients with NASH is 
significantl y different than in those with NAFLD.10The pooled liver -
specific and overall 
mortality  incidence rate estimates among those with NAFLD were calculated at 0.8 and 15.4, 
respectivel y, per 1,000 person -years.  In contrast, amongst the population with NASH, the 
incidence rate estimates were 11.8 (liver -specific) and 25.6 (overall) mortality .13  

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 17Elevated rates of hepatic DNL have been reported to be a distinctive characteristic of 
NAFLD.15Human subjects with elevated liver fat showed a more than 3- fold increase in the 
rate of hep atic DNL relative to subjects with normal liver fat, but no differences between the 
groups were detected in adipose free fatt y acid (FFA) flux or in production of VLDL from 
FFAs. 
A
sdescribed above, inhibition of ACC1/2 by  PF-05221304 and inhibition of DG AT2 b y 
PF-06865571 are anticipated to modulate lipid metabolism in distinct and complementary  
ways, suggesting that co- administration of both agents may  provide greater efficacy  than 
either agent alone.
1.3.Background Information for PF-05221304
1.3.1. Nonclinical Experience with PF -05221304
PF-05221304 has been orally  administered once -daily  for up to 16 weeks in toxicity  studies 
conducted in rats and monkey s.  In addition, PF -05221304 has been evaluated in genetic 
toxicity  studies, central nervous s ystem (CNS) and c ardiovascular safety pharmacology
studies, dose range -finding and definitive embry o-fetal development (EFD) studies in rats 
and rabbits, fertility  and earl y embr yonic study  in rats, and in vitro and in vivo phototoxicity  
studies.  The no observed adverse e ffect level (NOAEL) in the 16- week study  in rats was 
15mg/kg/day  (in males) and 5 mg/kg/day  (in females).  These doses were associated with 
total maximum plasma concentration (C max) of 6300 ng/mL (247 ng/mL, unbound) and total 
area-under -the-curve over do
sing interval of 24 -hours (AUC 24) of 40,300 ng•h/mL 
(1580 ng•h/mL, unbound) and total C maxof 1250 ng/mL (49 ng/mL, unbound) and AUC 24of 
10,100 ng•h/mL (396 ng•h/mL , unbound) for males and females, respectively .  The NOAEL 
in the 16- week stud y in monkey s was 30 mg/kg/day  for both sexes with associated total C max
of 30,600 ng/mL (293 ng/mL , unbound) and total AUC 24of 218,000 ng•h/mL  
(2080 ng•h/mL, unbound). 
In the rat CNS Safet y Pharmacology  study , higher numbers of vertical movements were 
noted in all dose groups (in a non- dose-dependent manner) compared with control animals.  
There were no other findings noted in that stud y on other measures of CNS activity 
(horizontal movements and functional observational battery ), and there were no CNS -related 
finding s in monkey  or rat toxicology  studies of up to 16 weeks in duration.  From the above, 
it is suggested that these findings are not likely  to lead to adverse events of concern in 
clinical trials.
Based on the nonclinical toxicity  studies conducted, the kidne y is considered a potential 
target based on moderate degeneration/regeneration of renal tubules in a single female 
monkey
 at 90 mg/kg/day  in the 2 week toxicity  study  in monkey s with the finding associated 
with minimal increase in blood urea nitrogen (BUN) ; however, these findings were not seen 
in the 16 week toxicity  study  in monkey s at the same dose (90 mg/kg/day ).  Additionally , 
observed adverse microscopic findings in the lung, skin, nonglandular gastric mucosa (rats) 
and non- adverse findings in the Har derian (rats) and Meibomian glands (monkey s), and in 
platelet production (monkeys), were likel y the result of exaggerated pharmacology and fatty 
acid deficiency . 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 18In embry o-fetal development ( EFD )studies, PF -05221304 resulted in fetal skeletal variations 
(rats and rabbits) plus fetal external and skeletal malformations (rabbits).  In a fertility  and 
early embr yonic study  in rats, all mating and fertility  parameters were similar for dose groups 
up to the highest dose of 30 mg/kg/day , and there were no effec ts on estrous cy cling or 
ovarian or uterine parameters in females, although female rats had lower weight gain before 
mating and during gestation, which was considered adverse.  There were no effects on early  
embry onic survival, or reproductive organ weight s or sperm parameters in the males. 
In a phototoxicity  study  in pigmented rats, there were no clinical signs or skin reactions 
indicative of phototoxicity  in the pigmented or non -
pigmented skin sites; as well as no 
changes in ophthalmology parameters or lig ht microscopic findings in the ey e (cornea, lens, 
and retina), at all of the PF -05221304 doses tested.
1.3.2. Clinical Experience with PF-05221304 
As of issuance of this protocol, a single clinical study (C1171001) has been completed with 
PF-05221304.  Four additional studies are ongoing: a 16 -week clinical study  (C1171002) in 
subjects with NAFLD, a single dose stud y evaluating the effect of hepatic impairment on 
pharmacokinetics ( PK)(C1171006) , a single dose absorption, metabolism and excretion 
study  (C1171010) and a fixed sequence combination study  to evaluate pharmacokinetic 
drug-drug interaction between PF -05221304 and PF -06865571 in health y subjects 
(C3711002; Section 1.5.2 ).  In C1171001, a total of 96 (93 male and 3 female) healthy  adult 
subjects were randomized.  Overall, 82 subjects (85%) were exposed to at least a single oral 
dose of PF -05221304; with 56 of these subjects exposed to repeated doses of PF-05221304 
for up to 14- days.  Single oral doses (from 1 mg to 240 mg) and repeated total daily  doses 
(from 2 mg/day to 200 mg/day  administered once -daily  or every  12hours) were found to be 
well-tolerated with an acceptable safety profile.  Over this dose range evaluated, whil e the 
maximum tolerated dose (MTD) was notidentified, higher doses were not assessed either 
because the a priori identified pharmacokinetic (PK) stopping limit was achieved (single 
dose) ornear complete inhibition of hepatic DNL was observed (with repeat ed dosing 
regimens evaluated). 
In the clinical program to date, there have been no serious adverse events (SAEs), 
notreatment -emergent adverse events (TEAEs) of ‘severe’ intensit y, and no apparent 
dose-related increase in frequency  or severity  of TEAEs a cross the 240 -fold (single) and 
100-fold (repeated) dose range studied.  All of the TEAEs were ‘mild’ in intensity  except 
1TEAE of ‘platelet count decreased’ deemed to be of ‘moderate’ intensit y; this resulted in 
premature withdrawal of 1 subject followin g 13 (of 14) days of PF -05221304 dosing at 
100mgevery  12hours ( Q12hr) (200 mg/day), the highest repeated dose evaluated.   This 
subject was as ymptomatic with no signs or s ymptoms of platelet dy sfunction and the 
decrease in platelet count did not meet cri teria for thrombocy topenia (defined as 
<100,000/mm3).  The platelet count increased towards baseline b y 72 hours post last dose 
and was back to baseline by  10days post last dose.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 19Upon single dose administration, the only  TEAE reported by  more than 1 subje ct was upper 
respiratory  tract infection (1 subject while on placebo and 2 subjects while receiving 
100mg).  Furthermore, with repeated dosing, the only  TEAE reported b y more than 
2subjects exposed to PF -05221304, across the entire dose range evaluated, was headache.  
All TEAEs were self -limiting requiring isolated use of concomitant medications and/or 
non-drug treatments to manage them.
Across the other safet y
-related data collected, drug -related, laboratory  parameter changes 
were observed although none were remarkable following single dose administration of 
PF-05221304.  Upon repeated dose administration of PF -05221304, identified adverse drug 
reactions (ADRs) include delevation in blood trigly cerides and reduction of platelet count.  
This included a gr adual increase in fasting and post -prandial serum trigl ycerides with 
repeated doses 
40mg/day with effect plateauing over the 14 -day dosing period.  At 
steady -state, the increase in mean fasting serum trigl ycerides (placebo -adjusted change from 
baseline) ranged from 35% -50% at doses 40mg/day; while increases in weighted- mean 
(AUC 24/24) serum triglycerides (placebo -adjusted change from baseline) ranged from 
20%-60%, at these same doses.  At the doses 60mg/day , a gradual decrease in platelet 
count was observed with repeated doses over the 14 day dosing period.  This observation was 
not noted at PF -05221304 doses up to 40 mg/day  and no signs or s ymptoms of platelet 
dysfunction were apparent based on the safety  assessments performed.  These ADRs have 
not be en observed with administration of single oral doses as high as 240 mg.  There were no 
apparent abnormalities noted in the other safety -related assessments such as blood pressure 
and cardiac conduction intervals [assessed on 12 -
lead electrocardiograms (ECG s)]. 
The plasma PK of PF -05221304 following oral administration suggests a moderate rate of 
absorption with a median time to maximum plasma concentration (T max) ranging from 3 to 
5hours, following repeated dosing with the morning meal.  Food (high -fat/high -caloric meal) 
had no clinicall y relevant effect on exposure which decreased slightly [area -under -the-curve 
to infinity  (AUC inf) by ~10% and C maxby ~25%], while rate of absorption was delay ed with 
Tmaxof 2.5 hours (dosing in fasted state) moving out to 5hours (when dosing occurred with 
food).  After attainment of C max, the disposition of PF- 05221304 showed a decline with the 
half-life of PF -05221304 being independent of dose, and ranging from approximately  
13to18hours.  Following single oral doses, the plasma PK parameters showed 
low-to-moderate variability  with % Coefficient of Variation (CV) for AUC infranged from 
16% to 36% and from 17 to 25% for C max.  Following single and multiple oral doses, mean 
apparent clearance (CL/F) ranged from 15 to 26 mL/min and mean volume of distribution 
(Vz/F) ranged from 20 to 31 L.  PF-05221304 has been determined to be highl y bound to 
plasma protein in humans.  L ess than 1% of the oral dose of PF -05221304 was excreted 
unchanged in the urine, indicating that renal c learance is not a major clearance mechanism 
for PF -05221304. 
Preliminary  assessment of circulating metabolites suggest sno concern of metabolites 
reaching exposures where Metabolites i nSafet y Testing (MIST) criteria need to be 
considered.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 201.4.Background Info rmation for PF -06865571
1.4.1. Nonclinical Experience with PF-06865571
PF-06865571 was evaluated in vitro and invivo in genetic toxicity  studies and safet y 
pharmacology  studies, in vivo in oral repeat -dose rat and monkey  toxicity  studies up to 
6weeks duration, and in an in vitro phototoxicity  assessment.  PF -06865571 was not 
mutagenic or clastogenic in invitro studies and was negative in invivo rat micronucleus 
studies.  No significant findings were noted in safety  pharmacology  invitro or in vivo in 
neuro -
pulmonary  and cardiovascular studies in rats and monkey s, respectively .  No adverse 
toxicity  and no target organs or s ystems were identified in Wistar Han rats or cy nomolgus 
monkey s following single or repeat doses (up to 6 weeks) of PF -06865571 via oral gava ge 
administration at doses up to 1000 (500 twice daily  [BID]) mg/kg/day .  These were 
maximum feasible doses based on dose volume and formulation limitations.  PF -
06865571 
did not demonstrate phototoxic potential in the neutral red uptake phototoxicity  assa y in 
mouse fibroblasts.   At this time, it is not known whether PF-06865571 can cause fetal harm 
when administered to pregnant women.
  Animal reproductive studies have not been 
conducted with PF -06865571.  I t is also not known whether PF -06865571 can affect male or 
female fertility
, or whether PF -06865571 is secreted in human milk. 
The NOAELs in the 6 -week studies were the highest dose levels tested, 1000 (500 BID) 
mg/kg/day  with associated unbound C maxand area under the curve over 24 hours (AUC 24) of 
2450/7880 ng/mL  and 25300/103000 ng•h/mL (males/females), respectively , in rats, and 
4790 ng/mL and 56900 ng•h/mL , respectivel y, in monkey s.  After correction for species 
differences in protein binding, the stopping criteria in humans are set to a C maxof 
6940 ng/mL and AUC 24of 71670 ng•h/mL (ie, NOAEL exposures observed in rats). 
1.4.2.
Clinical Experience with PF-06865571
As of issuance of this protocol, three clinical studies have completed dosing with 
PF-06865571: C2541001, C2541002, and C2541003.  C2541001 was the first study  in 
which PF-06865571 was administered to human subjects and was an investigator- and 
subject -blind, sponsor -open, randomized, placebo -controlled, single ascending, oral dose, 
2-cohort, interleaving design with placebo substitution, 4 -perio d crossover study  in which 
17healthy  adult subjects were exposed to at least one dose of PF -
06865571 ranging from 
5mg to 1500 mg.  C2541002 was the first clinical trial designed to administer repeated (up to 
14days) oral doses of PF -06865571 in the fed state to human subjects.  In C2541003, 
PF-06865571 pharmacokinetics (PK)of immediate release (I R) and modified release (MR) 
tablets of PF-06865571 was being compared to IR oral suspension under fed conditions.   
C2541005 is 
ongoing and is a Phase 1b, randomized double -blind (sponsor -open), 
placebo- controlled parallel group stud y designed to assess the safety, tolerability  
pharmacod ynamics and pharmacokinetics of multiple oral doses of PF-06865571 for 2 weeks 
in adults with NAFLD. 
In C2541001, PF -06865571 w as administered as an immediate release suspension.  PK data 
for 7 dose levels ranging from 5 mg to 1500 mgare presented below in Table 2.
PF-
06865571 was well tolerated with an acceptable safet y profile, and there were no serious 
adverse events (SAEs) reported.  A total of 16 adverse events ( AEs)which were deemed 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 21mild, were reported in C2541001 , for subjects receiv ingactive drug or placebo.  No 
clinically  significant trends in safet y laboratory parameters, creatinine levels, ECGs, and vital 
signs were observed over the range of doses administered in C2541001 .  The maximum 
tolerated dose was not identified . 
Following administration of single oral doses of PF-06865571 under fed conditions, median 
time for C max(Tmax) ranged from 1.5 to 4 hours across the dose groups.  Approximate 
dose-proportional increases in C maxand AUC 24were observed between the 5 mg and 
1500 mg doses.  Under fed conditions, the mean terminal t ½ranged from 1.5 to 5.2 hours.  At 
the 1000 mg dose level, exposures under fasted condition were approximately 2 -fold lower 
than those in the fed state.  Median PF- 06865571 T maxoccurred earlier in the fasted state, 
compared to dosing under fed conditions (1 hour versus 4 hours).  In addition, the terminal 
elimination half-life ( t½)under fasted conditions was more variable than under fed 
conditions.
Table 2. Summary of Plasma PF -06865571 PK Parameters Following Single Oral 
Doses in C2541001
Parameter Summary Statisticsafor PF -06865571 by Treat ment
Parameter 
(units)5 mg
Fed15 m g
Fed50 m g
Fed150 m g
Fed500 m g
Fed1000 m g
Fed1500 m g
Fed1000 m g
Fasted
N 6 6 6 5 6 6 5 6
AUC inf
(ng•hr/mL)64.69
(20)281.7
(31)742.3
(21)3354
(29)9738
(21)33160 
(25)39040 (17) 20120 (13)
AUC last
(ng•hr/mL )63.92 (21)279.3
(30)738.3
(21)3354
(29)9736
(21)33120 (25) 38970 (17) 19470 (11)
Cmax
(ng/mL)17.87 (25)73.01
(27)193.2
(29)785.7
(30)1820
(26)5257
(24)5356
(19)3470
(20)
Tmax
(hr)2.00 
(0.500 -4.00)1.50 
(0.500 -3.00)2.00 
(1.00 -4.00)3.00 
(2.00 -4.00)3.00 
(2.00 -4.00)4.00 
(3.00 -6.00)4.00 
(3.00 -6.00)1.00 
(1.00 -2.02)
t½
(hr)1.450 
0.2221.638 
0.1291.630 
0.5522.552 
0.4013.365 
1.1264.693 
1.6815.220 
3.13710.32 
6.95
Abbreviations: %CV = percent coefficient of variation; hr = hour; N = number of subjects in the treatment group and 
contributing to summary statistics; PK = pharmacokinetic(s); SD = standard deviation .
a.Geometric mean (geometric %CV) for all except: median (range) for T maxand arithmetic mean SD for t 1/2.
Clinical data from the C2541002 study are available. Following 14 days of dosing of 
PF-06865571 up to 600 mg every  8hours (Q8 hr) or placebo to healthy  subjects (n=60), there 
were a total of 112AEs, amajority  (103/112) of which were mild in intensity .  Of the AEs of 
moderate intensit y, 2AEs were due to venipuncture, and other moderate AEs were isolated 
occurrences and included nausea, vomiting, headache, penile discharge, generalized pruritus
without visible skin changes and presence of white blood ce
lls in the urine.  There was no 
evidence of increasing incidence or severity
 of AE with increasing dose.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 22There was one serious adverse event (SAE) in C2541002.  O ne subject who was assigned to 
receive 600 mg PF -06865571 Q8hr in Cohort 4 was noted to have a trial fibrillation detected 
by ECG on Day 7.  This episode of atrial fibrillation was not associated with any  symptoms 
or adverse changes in blood pressure and resolved spontaneously within 24 hours.  This 
episode prompted a brief hospitalization for less than 24 hours and was determined to be a 
SAE, and the subject discontinued dosing on Day 7.  The investigator considered the event to 
be possibly  related to study  treatment, and the subject was withdrawn from the study .  
Dosing for the remainder of subject s in this cohort was halted on Day 8, per protocol.  After 
investigator and Sponsor’s review of clinical data, dosing was resumed in a subsequent 
cohort (Cohort 5) at 400 mg Q8 hrfor 14 days.  After review of the clinical data of Cohort 5, 
Cohort 6 was adm inistered 600 mg Q8 hrfor 14 days.  This cohort completed dosing for the 
planned period of 14 days.
No clinically -significant trends in safet y laboratory parameters, ECGs, orvital signs have 
been observed in clinical studies to date .  However, preliminary data indicate that creatinine 
levels increased slightl y with dose.  At doses of 100 mg Q8 hrand above, median creatinine 
levels increased b y approximately  0.15 to 0.2 mg/dL compared to baseline, but returned to 
baseline levels at follow -
up.  The organic c ation transporter 2 (OCT2 )and/or multi- drug and 
toxin extrusion protein (MATE) inhibition by DGAT2 has been shown to affect creatinine 
levels.16Therefore, these changes are not necessarily  reflective of changes in glomerular 
filtration rate (GFR) and instead may  be due to OCT2 and/or MATE inhibition.  Cystatin C 
levels, a marker of kidney function whose levels are not affected b y OCT2/MATE inhibition, 
were measured in C2541002 and review of these data demonstr ated no clear changes. 
Based on overall AE and safet y laboratory  assessment, PF-06865571 was generall y safe and 
well tolerated at the doses tested in study  C2541002.
Steady  state (Day 14) PK revealed an approximately  dose proportional increase in 
PF-
06865571 exposure.  Steady  state appeared to be attained by  Day 1 due to the short 
elimination half -life.  The median peak to trough ratio (PTR) was approximately  10-fold 
across the cohorts.  A summary  of multiple -dose PK data in C2541002 is presented in 
Table 3.  Less than 2% of the total dose was eliminated renally  across the dose range 
evaluated.
Table 3. Summary of Preliminary Steady State (Day 14) Plasma PF -06865571 PK 
Parameters Following Multiple Oral Dos
es in C2541002
Param eter (units) 30 m g Q8 hr 100 m g Q8 hr 240 m g Q8 hr 400 m g Q8 hr 600 m g Q8 hr
Cmax (ng/mL) 171.5 (38) 665.6 (43) 1520 ( 29) 25 98 (22) 3527 (36)
Tmax (hr) 2.03 (1 -3.02) 2.01 (1 -3) 2.5 (1-3) 2 (2-3) 3.0 (1.05 -4)
AUC tau (ng•hr/mL) 652.5 (36) 2619 (47) 5717 (32) 10,830 (1 5 ) 1 7010 (38)
t1/2(hr) 3.294 (46) 4.365 (48) 4.096 (13) 3.840 (27) 6.916 (33)
PTR 10.85 (58) 10.15 (62) 9.693 (65) 8.988 (53) 5.178 (49)
Geometric mean (%CV) for C maxand AUC.   Median (range) for T maxand arithmetic mean (%C V) for t 1/2; NA -not 
available; All values reported as below limit of detection ( BLQ )
have been replaced with zero for all calculations.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 23Biomarker data used to assess potential for cytochrome P450 ( CYP )3A induction (plasma 
4-hydroxy cholesterol/cholestero l and urinary 6-hydroxy cortisol/cortisol ratios) indicate no 
clinically  meaningful changes from baseline relative to placebo.  Additionally , PF-06865571 
Day 14 exposure was approximately  dose proportional in C2541002, indicating no 
auto- induction of metab olism of PF -06865571 with multiple oral doses.  Together, these data 
suggest that PF -06865571 is not a clinically  meaningful inducer of CYP3A.
In addition, the potential of PF- 06865571 to inhibit OCT2/MATE was assessed in C2541002 
by evaluation of renal clearance of N -methy lnicotinamide (NMN), an endogenous substrate 
for OCT2 and MATE transporters .  PF-06865571 doses of 400 mg and 600 mg Q8 hr, but not 
lower doses, appeared to have numerically
 greater reductions from baseline in renal 
clearance of NMN compar ed with placebo suggesting potential inhibition of OCT2/MATE 
transporters . These changes are consistent with the in vitro data indicating that PF - 06865571 
may be an OCT2/MATE1 inhibitor.
Study  C2541003 was a Phase 1, open- label study  in healthy  subjects to investigate the PK of 
PF-06865571 following single oral administration of I R and MR tablets compared to oral 
suspension under fed conditions.   A single oral dose of 150mg PF-06865571 was 
administered as IR suspension, I R tablets, and slow and fast releas e MR tablets under fed 
conditions in order to mimic the anticipated conditions of actual clinical use.  In this study , 
PF-06865571 demonstrated an acceptable safety  and tolerability  profile.
  PF-06865571 C max
and AUC values from I R suspension and tablets w ere similar to each other and met the 
bioequivalence (BE) criteria.
1.5. Background Information on PF- 05221304 and PF -06865571 Combination
1.5.1. Non-Clinical Experience with Combination of PF-05221304 and PF -06865571 
Platelet lowering is thought to be a class effect of ACC inhibition resulting from significant 
inhibition of DNL  in the bone marrow leading to impaired megakary ocyte (MK) maturation. 
Consistent with this information, reductions in platelets have been observed as a non -adverse 
event in monkey s with PF -05221304.  However, reductions in platelet counts were not 
observed in cy nomolgus monkey  toxicology  studies with the DGAT2 inhibitor PF -
06865571, 
or in clinical studies with that compound.  Monkeys were selected for combination toxicity  
testing because monke ys are sensitive to the effects of PF -
05221304 on platelets, whereas, 
rats are not.  In addition, monkey s are also a relevant species to test any  impact of DGAT2 
inhibition on PF -05221304 platelet lowering. 
A pivotal 6 -week repeat -dose toxicity  study  was conducted in cy nomolgus monkey s with 
PF-05221304 and PF- 06865571, alone and in combination.  In this study , monkey s were 
administered 30 or 60 QD (quodque die, (once daily )) mg/kg/day  PF-05221304 alone, 30 or 
60(QD) mg/kg/day  PF-05221304 in combination with 300 (150 BID) mg/kg/day  
PF-06865571, or 300 (150 BID) mg/kg/day  PF-06865571 alone.  Test -article -related findings 
in the 60 (QD) mg/kg/day  PF-05221304 alone and 60 (QD) mg/kg/day  PF-05221304 in 
combination with 300 (150 BID) mg/kg/day  PF-06865571 consis ted of adverse bod y weight 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 24loss and dehy dration, and non- adverse changes in hematology  and clinical chemistry  
parameters. 
Co-administration of 300 (150 BID) mg/kg/day  PF-06865571 did not alter the toxicity  
associated with 60 (QD) mg/kg/day  PF-05221304.  The toxicokinetics of PF -06865571 and 
PF-05221304 were not affected b y co-administration.   The oral administration of up to 
60(QD) mg/kg/day  PF-05221304 and/or 300 (150 BID) mg/kg/day  PF-06865571 alone or in 
combination to cy nomolgus monkey s for 6 weeks di d not result in mortality or an y test 
article -related changes in mean body  weights or mean body  weight changes, ECG 
parameters, mean organ weight ratios, coagulation or urinal ysis test results, and no test 
article -related macroscopic or microscopic observa tions were noted.
  The few test 
article -related clinical pathology findings noted on Day 43 were all considered non -adverse 
due to their small magnitude and lack of correlative clinical or microscopic findings. The 
non-adverse test article -related hematol ogy finding was mildly  to moderately  decreased 
platelet count (0.37x -0.55x baseline) in 1 male and 1 female administered 
60(QD) mg/kg/day  PF-
05221304 alone and 1 male (Animal P0503) administered 
60(QD) mg/kg/day  PF-05221304 with 300 (150 BID) mg/kg/day  PF-06865571.   The 
non-adverse, test article -related clinical chemistry  findings were minimally  decreased 
albumin (0.81x
-0.85x baseline) in animals administered 60 (QD) mg/kg/day  PF-05221304 
alone or with 300 (150 BID) mg/kg/day  PF-06865571 and mildly  decrea sed cholesterol 
(0.55x -0.61x baseline) in animals administered 30 (QD) or 60 (QD) mg/kg/day  PF-05221304 
with 300 (150 BID) mg/kg/day  PF-06865571. 
In monkey s, doses of 30 (QD) mg/kg/day  PF-05221304 and 300 (150 BID)mg/kg/day  
PF-06885571, alone or in combi nation, were considered the no observed adverse effect levels 
(NOAEL) for each respective and combined test articles based on a lack of adverse findings.  
The anticipated exposures of PF- 05221304 at 15 mg BID in this study  are 122 -fold and 
29-fold lower (Cmaxand AUC 24, respectively) than the NOAEL (30 mg/kg(QD) 
PF-05221304 + 300 mg/kg(BID) PF - 0686557 1) in the 6 -week combination toxicology  study  
in monkey s.  Similarly , the anticipated exposures of PF -06865571 at 300 mgBID in this 
study  are 3.7 and 6.2 -fold lower than the 6 -week monkey  NOAEL.  The dose of 
60(QD) mg/kg/day  PF-05221304, alone or with 300 (150 BID) mg/kg/day  PF-06865571, 
was adverse due to the severity  of body  weight loss and/or deh ydration with concomitant 
fecal abnormalities for 1 male in each group that required supportive fluid therap y and dose 
suspension for 1 male. 
1.5.2. Clinical Experience with Combination of PF-05221304 and PF- 06865571
At the issuance of this protocol, C3711002, the first clinical study  testing co -administration 
of PF -05221304 and PF -06865571, is underway .  C3711002 is designed as a Phase 1, open 
label, multiple dose, 2 -cohort, non -randomized, fixed -sequence stud y to evaluate the 
pharmacokinetic drug -drug interaction (DD I) between PF -05221304 and PF- 06865571, and 
safet y and tolerability  of in healthy  adult subjects .  Each of the Investigational Product s(IPs)
is being administered orally  twice daily . 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 25A total of 16 subjects were enrolled in this study  (N=7 in Cohort 1, N=9 in Cohort 2).  In 
Cohort 1, subjects received PF -05221304 15 mg Q12hr (every  12hours) on Day s 1-7 and 
PF-05221304 15 mg Q12hr plus PF -06865571 300 mg Q12hr on Day s 8-13.  On Day 14, 
subjects received PF -05221304 15 mg plus PF -06865571 300 mg once (AM only ).  In 
Cohort 2, subjects received PF -
06865571 300 m g Q12hr on Day s 1-7 and PF - 05221304 
15mg Q12hr plus PF -06865571 300 mg Q12hr on Day s 8-13.  On Day 14, subjects received 
PF-
05221304 15 mg plus PF -06865571 300 mg once (AM onl y).  All doses in this study  
were administered with food.  Pharmacokinetic parameters were compared on Day 14 
(combination) versus Day
7 (each agent administered alone ).  Additionally , safet y and 
tolerability  were assessed for each subject.  C3711002’s dosing period is completed and a 
summary  of the available preliminary  data is provi ded below. 
Safety Summary
In Cohort 1, after 7 days of dosing PF -05221304, followed by  7days of combined dosing of 
PF-
05221304 and PF- 06865571, a total of 9 AEs were reported in 5 subjects, with 6 AEs 
categorized as mild and 3 as moderate in severit y. 
The 3 AEs of moderate severit y were reported in one subject and corresponded to concurrent 
elevations in alanine aminotransferase ( ALT), aspartate aminotransferase ( AST )and 
gamma -glutamy l transferase ( GGT ).  The subject started the study  with a minor eleva tion in 
baseline 
ALT (59 Units/Liter ( U/L) ).  Asymptomatic i ncreases in ALT and AST were 
detected on scheduled safety  labs on Day 7 while dosing PF -05221304 alone.  ALT peaked at 
187U/L (3.8x upper limit of normal ( ULN) )and AST peaked at 116 U/L (2.9x UL N) on 
Day 8, prompting precautionary  discontinuation of the subject from the study  on Day 9, after 
completing one full day  of dosing of the PF-05221304 and PF -06865571 combination.
  Total 
bilirubin and alkaline phosphatase remained normal.  Upon further re view of the 
pre-randomization labs, it was found that the subject had high GGT at baseline (123 U/L; 
Normal L imit R ange=0
-73U/L).  The subject’s liver function tests re turned to baseline 
values on Day 22 of the study .  The subject remained as ymptomatic th roughout the entire 
period.
Preliminary  anal ysis of safet
y laboratory  data from Cohort 1 was notable for the following 
observations.   A mild elevation in AL T (~1.4x ULN) was observed in 2 other subjects on 
Day 7 of the monotherapy  dosing period with PF -
05221304.  In both cases AL T returned 
within normal range with continued dosing, which included completion of the 7 -day period 
of combined dosing with PF -
05221304 and PF- 06865571.   These elevations were not 
considered as AEs.
Two subjects had increases in tri glycerides exceeding ULN with peak values at Day 10 of 
212mg/dL and 255 mg/dL respectivel y.  Both subjects trended down on Day 14, one subject 
with continued dosing. The second subject is the same one that was discontinued as a 
precautionary  measure due 
to ALT elevation >3 x ULN (see above). 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 26One subject with a baseline platelet count of 156,000/mm3(lower limit of normal 
(LLN )=150,000/mm3) had platelet count dip slightly  below normal with a nadir of 
138,000/mm3and remained stable at approximately that l evel throughout the study .  Platelet 
values for all other subjects remained within normal limits. 
A slight trend for increase in serum creatinine was observed after Day 7, which remained 
stable at Day 14, returning towards baseline at follow -up.  All values remained within the 
normal range for the whole period of observation.   Cystatin C remained within the normal 
range with minor fluctuations during this period.   Thus, these observations are interpreted as 
consistent with an effect of PF -06865571 to inhib
it OCT2/MATE and not necessarily  
reflective of changes in glomerular filtration rate or renal function .  No clinically  significant 
trends in other safety  laboratory  parameters, ECGs or vital signs were observed in Cohort
1. 
In Cohort 2, after 7days of do sing PF -06865571, followed by  7days of combined dosing of 
PF-06865571 and PF- 05221304, a total of 17 AEs were reported in 7 subjects, with 13 AEs 
categorized as mild and 4 as moderate in severit y.  Two of the 4 moderate severit y AEs 
corresponded to a conc urrent episode of, respectively , nausea and vomiting in one subject.   
The other 2 moderate severity  AEs corresponded to left back pain and headache in another 
subject.  All AEs resolved without sequelae. 
Preliminary  anal ysis of safety laboratory  data from Cohort 2 was notable for the following 
observations.   One subject had a mild elevation in AL T to 58 U/L (ULN<49 U/L), detected 
on scheduled safet y laboratories in Day 7 while receiving PF -
06865571.  ALT increased 
slowly  with peak value of 99 U/L on Day 10, then decreasing towards baseline with 
continued dosing, which included 
completion of the 7 -day period of combined dosing with 
PF-06865571 and PF- 05221304 .  AL T v alues reached baseline b y Day 21. 
A slight trend for increase in creatinine was observed fro m baseline to Day 7 with dosing of 
PF-06865571 alone, with average increase in creatinine of approximately  0.05 mg/dL and 
remaining stable through the rest of the dosing period.  All creatinine values remained within 
normal limits and values were trending back to baseline by  Day 22 (follow up visit).
  
Cystatin C trended slightly  up with all values remaining well within normal limits.   These 
observations are again interpreted as consistent with an effect of PF- 06865571 to inhibit 
OCT2/MATE and not necessaril y reflective of changes in glomerular filtration rate.   Three 
subjects in this cohort had increases in fasting trigly cerides exceeding ULN with peak values 
at Day 14of 166mg/dL, 196 mg/dL and 2 23mg/dL respectivel y.  All subjects trended down 
on Day 22 w ith continued dosing . 
No clinically  significant trends in other safet
y laboratory parameters, ECGs or vital signs 
were observed in Cohort 2. 
No SAEs have been reported in the study , to date . 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 27PK Summary
Preliminary  PF-05221304 plasma PK parameters when a dministered alone (Day 7) or with 
PF-06865571 (Day 14) have been summarized below in Table 4.  PF -05221304 AUC 12was 
modestly  lower (~19%) when administered with PF -
06865571 versus alone.
Table 4. PF-052213 04 PK Parameters following Administration of PF -05221304 
Alone (15 mg BID) or with PF
-06865571 (300 mg BID) in C3711002
Param eter (units)PF-05221304 
Alone (Day 7)PF-05221304 + 
PF-06865571 (Day 14)GMR (90%CI)
AUC tau (ng•hr/mL )12130.35 (25.80%) 9482.76 (23.03%) 0.81(0.74,0.88)
Cmax (ng/mL) 1337.03 (25.08%) 1128.14 (19.94%) 0.88(0.80,0.98)
Tmax (hr) 4.00 (2.00 -6.00) 2.00 (1.50 -4.00) NA
Geometric mean (%CV) for C maxand AUC.   Median (range) for T max; NA =not applicable; 
GMR=Geometric Mean Ratio (Day 14 /Day 7); CI= confidence interval.
Preliminary  PF-06865571 plasma PK par ameters of administered alone (Day 7) or with 
PF-05221304 (D ay14) have been summarized in Table 5.  PF -06865571 pharmacokinetics 
are essentially  unchanged w hen administered with PF -
05221304 versus alone.
Table 5. PF-06865571 PK Parameters following Administration of PF -06865571 
Alone (300 mg BID) or with PF 05221304 (15 mg BID) in C3711002
Param eter (units)PF-06865571 
Alone (Day 7)PF-06865571 + 
PF-05221304 (Day 14)GMR (90%CI)
AUC tau(ng•hr/mL) 8716.33 (18.73%) 9436.24 (33.88%) 1.08(0.97,1.21)
Cmax(ng/mL) 2385.54 (9.56%) 2579.70 (20.71%) 1.08(0.98,1.19)
Tmax(hr) 2.00 (1.00 -4.00) 2.00 (1.00 -2.00) NA
Geometric mean (%CV) for C maxand AUC.   Median (range) for T max; NA =not applicable; 
GMR=Geometric Mean Ratio (Day 14/Day 7); CI= confidence interval; 
Additional information for PF- 05221304 and PF -06865571 may  be found in the single 
reference safet y document (SRSD) for each compoun d, which are the Investigators’ 
Brochures (IBs) for PF -05221304 and PF -06865571, respectivel y. 
1.6.Study Rationale
The objective of this study  is to assess the effect of PF -05221304 alone, PF-06865571 alone, 
the co-administration of PF-05221304 and PF -0686557 1,or placebo on whole liver fat in 
subjects with NAFLD.  In addition, this study  will evaluate the safet y and tolerability of 
co-administration of PF-05221304 and PF- 06865571 along with the effects on selected 
pharmacod ynamics ( PD)/exploratory  parameters, compared to administration of 
PF-05221304 alone, PF -06865571 alone, and placebo in adults with NAFLD.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 281.6.1. Design Rationale
To address the potential effect of PF-05221304 and PF -06865571 co- administration on liver 
fat, the eligible population for study  enrollm ent is subjects with NAFLD, defined as having 
liver fat 8%, as assessed by  magnetic resonance imaging -proton density  fat fraction 
(MRI -PDFF) at Screen
ing Visit 3.  In an effort to help identify  these subjects, evidence of 
concomitant medical conditions kn
own to predispose subjects to NAFLD, including features 
of metabolic s yndrome or T2DM will be utilized.   FibroScanassessments will be done at 
Visit 1 (Screen 1) and Visit 2 (Screen 2) to help initially  estimate liver fat using a more 
scalable and cost -efficient approach than MRI -PDFF.  Subjects who meet all eligibility  
criteria for the stud y during Screen 1 will proceed to Screen 2 for an additional liver fat 
approximation by  FibroScan.  Two assessments using FibroScan will be used because of the 
variabi lity in fat determination with Controlled Attenuation Parameter (CAP ), measure of 
liver fat content .  These assessments will provide a more accurate initial estimate of liver fat 
prior to MRI -PDFF.   Subjects will then undergo liver fat assessment b y MRI- PDFF
(Screen 3) for confirmatory  purposes .
For the assessment of liver fat (either via FibroScanor MRI -PDFF), subjects will be 
required to fast (water permitted) for 4hours given the ability  of food to impact the results.  
In order to limit measurement variability , the nominal time for FibroScanand MRI -PDFF 
assessments will be standardized .  Baseline assessments for MRI -PDFF and FibroScan
(Visits 
5and 6, respectively ) should fall within a practical window ( 2 hours) relative to 
clock time of the initial screening visit for each assessment.  All post -randomization 
assessments for both MRI -PDFF and FibroScanshould occur within a practical window 
(2hours) relative to clock time of the baseline visit for each assessment (ie, Visit 5and 6, 
respective ly).
A
fixed, single- blind placebo run- in period of approximately  14days (from Visit 4 to Visit 6) 
following confirmation of eligibility  and pri or to randomization is included to familiarize 
subjects with the study  treatment regimen and to exclude subject s who are not compliant with 
single -blinded placebo administration p rior to randomization at Visit 6.  To date, clinical 
experience with PF-05221304 and PF -06865571 co
-administration is limited to a PK 
drug-drug interaction (DDI) study  (C3711002) with a total of 1 week duration of combined 
drug exposure in an inpatient setting .  In this study, with longer and predominantly  outpatient 
dosing in a patient population, close safet y monitoring will be implemented with frequent 
(every 2weeks) outpatient visits p ost randomization ,including an additional , earl yvisit at 
Day 5 (Visit 7). 
Total duration of PF-05221304 and PF -06865571 co
-administration in this study will be 
approximately  6weeks, supported b y a completed 6-week non - clinical combination toxicity  
study in monkey s.  This duration is expected to allow assessment of effects of 
co-administration of PF-05221304 and PF- 06865571 on liver fat content , as well as on safet y 
and tolerability  of these agents. 
In this stud y PF-05221304 and PF -06865571 co -administr ation will be required to occur 
twice dail y with food (breakfast and dinner) . 

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 29This study is designed to assess the effect of PF-05221304 and PF-06865571 on liver fat and 
other PD biomarkers that are intended to provide insight into m etabolic pathways related to 
ACC and DGAT2 inhibition.  Specifically, the study will evaluat e the effect of PF-05221304 
and PF-06865571 combination on liver fat and liver function [ie , alanine aminotransferase 
(ALT), aspartate aminotransferase (AST), alkaline phosphatase an d gamma-glutamyl 
transferase (GGT)], glycemic parameters, and fasting lipids incl uding total cholesterol, 
low-density lipoprotein cholesterol (LDL-C), high-density lipop rotein cholesterol (HDL-C) 
and triglycerides (TGs).  In addition, effect on other PD param eters [ie apolipoproteins A1, 
B (total), C3, , proprotein convertase subtilisin/kexin type 9 (P CSK9)  
 and certain NASH-related biomarkers] will be 
assessed.  
 
 
 
 
 
 
Creatinine is actively secreted by OCT2/MATE in kidney.  In the  setting of OCT2/MATE 
inhibition, serum creatinine levels have been reported to incre ase slightly.  In accordance 
with reported literature on OCT2/MATE inhibition, minor increas es in serum creatinine have 
been observed in C2541002, a 2-week multiple dose ascending stu dy for PF-06865571, with 
very limited change in cystatin.  In order to better assess rena l function in the setting of 
possible PF-06865571-induced OCT2/MATE inhibition resulting in spurious serum 
creatinine increases, serum cystatin C will be assessed as part of the standard safety labs, in 
addition to serum creatinine, in order to accurately interpret potential changes in glomerular 
filtration rate (GFR).
Interim analysis (IA) may be performed [refer to Section 9.8 ] to permit a review of safety 
and pharmacodynamics of the population enrolled, amongst the pl anned activities. 
1.6.2. Rationale for Population Enrolled
The study population included in this study will be overweight or obese subjects (body mass 
index [BMI] ≥25 kg/m2) with clinical indicators of metabolic syndrome and/or T2DM. 
Although NAFLD is a condition with excessive fat accumulation in  the liver defined as ≥5%, 
this study will enroll subjects with liver fat values ≥8% at screening to allow for potential 
measurement variability and help ensure baseline liver fat valu es are likely to be ≥5%.  As it 
is unknown whether subjects with lower versus higher baseline l iver fat values may respond 
differently to therapy, subjects will be stratified at randomiz ation (Visit 6) based on CCICCI CCI
CCI
CCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 30MRI -PDFF (Screen 3) liver fat ranges of 8% to <1 5%; and  15% as a means of balancing 
liver fat content between dosing cohorts.   A second - tier stratification will also be applied at 
randomization based on the presence or absence of T2 DM (refer to Section 4.3 for additional 
details regarding stratification).
T2DM subjects will be permitted to be on a stable dose of up to 1 acceptable oral drug for 
glycemic control.   These may  include sulphony lureas , dipeptidy l peptidase -IV inhibitors 
(DPP -IVi) and meglitinide s.  However, t hiazolidinediones (TZDs) , glucagon -like peptide-1 
receptor (GLP -1r) agonists and sodium -glucose co -transporter 2 (SGLT2) antagonists are not 
permitted given their reported an ti-steatotic effect that may  potentiall y confound the effect of 
study  drugs on primary  endpoint of this study .  Metformin is not permitted due to the 
potential risk for OCT2/MATE inhibition by PF- 06865571 resulting in a drug-drug 
interaction ( DDI)potentia lly increasing m etformin exposure.  Refer toSection 5.8for 
complete details regarding permitted and excluded concomitant medications.
Eligible women will be confirmed to be of non -childbearing potential sinc e at the present 
time embry o-fetal developmental toxicology  studies with PF -06865571 have not y et been 
conducted andexposure to 
PF-05221304 in embryo -fetal developmental toxicology  studies 
has been shown to result in fetal skeletal variations (rats and ra bbits) plus fetal external and 
skeletal malformations (rabbits).   In eligible men, appropriate measures to minimize potential 
transfer of PF-05221304 or PF -06865571 via semen to a woman of childbearing potential are
expected to be followed [refer to Section
4.4.4]. 
1.6.3. Dose Rationale
This study  is planned as a 2x2 factorial, 4-arm, parallel group study  with 1placebo arm, 
1active 
dose arm of PF -05221304 (15 mg, Q12 hr), 1active dose arm of PF-06865571 
(300 mg, Q12 hr) and 1 active dose arm for co- administration of PF -05221304 (15 mg, 
Q12hr) and PF -06865571 (300 mg, Q12 hr).
The objective of this study  is to assess the effect of PF -
05221304 alone, PF-06865571 alone, 
the co-administration of PF-05221304 and PF -06865571, or placebo on whole liver fat in 
subjects with NAFLD.  Additionally , the study  is designed to further characterize the safety  
and tolerability  of PF-05221304 and PF-06865571 when co- administered versus each agent 
given alone.  Lastl y, the ability  of PF -
06865571 to mitigate possible increases in plasma 
triglycerides that are associated with PF -05221304 dosing when high levels of hepatic DNL 
inhibition are achieved will be explored. 
As data are not available at this time regarding the eff ect of PF -06865571 on liver fat in 
patients with NAFLD, a dose was selected (300 mg BID) that is projected to achieve average 
daily  concentration 4 -fold higher than the projected unbound human efficacious 
concentration ( Ceff)[120 nM ( 48.9 ng/mL) ]
.  This d ose is also the highest dose being 
examined in an ongoing 2
-week stud y assessing the effect of PF -06865571 on liver TG in 
subjects with elevations in liver fat.   A total dail y dose 2 fold higher than the PF -06865571 
dose proposed for this study  has been we ll tolerated with an acceptable safety  profile in the 
multiple ascending dose study  (C2541002).

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 31A dose of 15 mg BID was selected for PF- 05221304 in this study .  Although PF -05221304 
has a pharmacokinetic half -life conducive to once daily  dosing, a Q12hr do sing regimen was 
selected to match the profile of a combination product (Q12hr dosing likely needed due to 
short half -life of PF -06865571).  The 15 mg Q12hr dose is expected to y ield simi lar average 
daily  hepatic denovo lipogenesis inhibition (88%) as the top dose of 50 mg QD in the 
ongoing 16 week P hase 2a study (C1171002) in subjects with elevated liver fat (90%).  The 
dose of 15 mg Q12hr is approximately  6fold less than the highest dose tested in C1171001 
(100 mg Q12hr).
1.6.4. Rationale for Banked Biospecimen Collection
In this stud y, subject to regulatory and ethics approval/favorable opinion, an additional 
research component includes collection of blood for Prep D1.5, Prep B1.5, and Prep B2.5
(see Section 7.7) for possible exploratory  anal yses.  These retained pharmacogenomic and 
biomarker collections will be undertaken as a means to enable the exploration of the 
contribution of genomic and other biomarker variations to the observed variability  in PK of, 
and for response to, PF -05221304 and PF -06865571 and wider research investigation, as 
permitted by subject consent .
Banked biospecimens will be collected for the purpose of conducting research; specific uses 
are described in the Banked Biospecimens section.  Comparing the deoxy ribonucleic acid 
(DNA), ribonucleic acid (RNA), protein, and metabolite variation patterns of subjects who 
respond well and those who respond poorl y to treatment may help to better define the most 
appropriate group of subjects in which to target a given treatment.  Collecting biospecimens
for exploratory  pharmacogenomic/genomic/biomarker anal yses and retaining them in the 
Biospecimen Banking S ystem (BBS) make sit possible to better understand the 
investigational product’s (IP) mechanism of action and to seek explanations for differences 
in, for example, exposure, tolerability , safet y, and/or efficacy not anticipated prior to the 
beginning of the stud y. 
Banked biospecimen s
retained i n the BBS can also be used in research on non-alcoholic fatty  
liver disease or related metabolic disorders .
Providing these biospecimens is a required stud y activity  for study  sites and subjects, unless 
prohibited by  local regulations or ethics committee (EC) decision. 
2.STU DY OBJECTIVES AND EN DPOINTS
Prim ary Objective(s): Prim ary Endpoint(s): 
To determine the effect of co -administration of 
PF-05221304 and PF -06865571 on w hole liver fat 
compared to placebo, PF -05221304 administered 
alone, and PF -06865571 administered alone in 
subjects with NAFLD.Relative change from baseline in whole liver fat at 
Day 42, as assessed by magnetic resonance imaging 
proton density fat fraction (MRI -PDFF) .
Secondary Objective(s): Secondary Endpoint(s): 
To evaluate safety and tolerability of PF-05221304 
and PF -06865571 co -administration compared to Assessment of treatment -emergent adverse events 
(and serious adverse events), clinical laboratory tests 

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 32placebo, PF-05221304 administered alone, and 
PF-06865571 administered alone in subjects with NAFLD.including lipids, vital signs, and 12-lead 
electrocardiograms.
Tertiary/Exploratory Objective(s): Tertiary/Exploratory Endpoin t(s): 
To evaluate the effect of co-administration of 
PF-05221304 and PF-06865571, on liver function 
tests (LFTs) compared to placebo, PF-05221304 administered alone, and PF-06865571 administered alone in subjects with NAFLD.Percent change from baseline at all time points for:
•ALT, AST.
•Alkaline Phosphatase.
•Gamma-glutamyl transferase (GGT).
To evaluate effects of co-administration of 
PF-05221304 and PF-06865571 on lipids compared to placebo, PF-05221304 administered alone, and 
PF-06865571 administered alone in subjects with 
NAFLD.Percent change from baseline at all time points for:
•Triglycerides.
•Total cholesterol, HDL-C, direct LDL-C, Total 
cholesterol/HDL-C ratio, and non-HDL-C.
 
 
 
 
  
 
 
  
To evaluate the PD effects of co-administration of 
PF-05221304 and PF-06865571 compared to 
placebo, PF-05221304 administered alone, and 
PF-06865571 administered alone, in adults with NAFLD.Analyses for PD parameters: 
•% Change from baseline to Day 42 in 
Apolipoproteins (A1, B100 and C3).
 
•% Change from baseline to Day 42 in plasma 
PCSK9.
 
  
 
To collect banked biospecimen for exploratory
research, unless prohibited by local regulation or ethics committee decision.Collection of banked bio-specimens unless prohibited 
by local regulations or ethics committee decision.  Additional information on collection and potential use is provided in Section 7.7CCI
CCI
C
CI
CC
I
CCI
PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 333. STUDY DESIGN
3.1. Study Overview
This is a randomized, double-blind (sponsor-open), placebo-contro lled, 2x2 factorial, 4-arm 
(placebo, monotherapy of PF-05221304, monotherapy of PF-0686557 1 and combination of 
PF-05221304 and PF-06865571), parallel group study (Figure 1).
Figure 1. C3711001 Study Design
Determination of eligibility for this study will occur via a se quential, 3-step process, starting 
at the first screening visit (Screen 1).  Subjects identified to  be eligible based on Screen 1
AND Screen 2 procedures will proceed to Screen 3 to measure liver fat by MRI-PDFF.  For a 
given subject, this 3-step eligibility assessment may take up to  6 weeks.
Once confirmed to be eligible based on results of Screen 3, subj ects will progress to a Run-in 
period (Visit 4), at which time subjects will receive single-bli nd placebo for approximately 
14 days to ensure compliance with the administration of IP.  App roximately 4 days prior to 
randomization, subjects will report to the imaging center (Visit 5) to have a baseline 
MRI-PDFF scan performed.  At Visit 6 (Day 1), subjects will be ran domized to receive 1 of 
4 blinded IP regimens (placebo, PF-05221304 monotherapy, PF-0686 5571 monotherapy, or 
PF-05221304 plus PF-06865571 combination) for a duration of up to 6 weeks (ie, 42 days).  
This study includes a total of 11 scheduled outpatient visits to  the study site, including 
4 visits to the imaging center, and a safety Follow-up telephone  contact.  The total 
participation, from Visit 1 (Screen 1) to Follow-up telephone phone  call will be up to 
approximately 19 weeks. CCI
CCICCICCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 34Approximately  98subjects (1 4 for the placebo group, 28for each of the m onotherapy  groups 
and 28 for the combination group) will be randomized at approximately  30sites (refer to 
Section
9.1). 
Subjects who are noted to have non -evaluable baseline MRI -PDFF, as determined by  the 
sponsor -identified central imaging vendor, should have their MRI -PDFF repeated once; if the 
images are still non-evaluable on single -repeat, the subject will be considered as screen 
failed; 
otherwise, there are no plans to replace subjects who are prematurel y withdrawn.
3.2. Stopping Rules in Individual Subjects
At investigator discretion, for subjects’ safet y, dosing with an y of the double -blinded 
investigational product(s) (ie, post randomization), may  be stopped in an individual 
subject -either temporarily  or permanently .  An y treatment -related SAE will result in 
permanent discontinuation of the subject.   Any open TE AEs must be followed to resolution 
or until such time that the event is viewed to have stabilized–refer to Section 8for details .  Of 
note, subjects who meet threshold for withdrawal based on platelet count (see Appendix 3) or 
fasting serum 
triglycerides ( see Appen dix4), should not be re -challenged with 
investigational product.   Additionally , a subject may not cross -over t o another group, once 
randomized to a particular group.
An example where temporary discontinuation of dosing with investigational product(s) may  
be considered includes hospitalization with subsequent discharge within 7-days in stable 
medical condition, as determined by  medicall y
-qualified investigator .  Examples where 
permanent discontinuation of dosing and withdrawal of the subject from the study  is deemed 
appropriate, as determined by  investigators’ medical judgment, include:
Hospitalization due to serio us adverse event (SAE) resulting in clinical 
decompensation of the subject and necessitating continued inpatient stay  for more 
than 7
-days.
Subjects observed to have a decline over time ultimately  reaching the threshold of 
<75,000/mm3in platelet count –refer to Appendix 3for additional guidance.
Individual subjects with consistently  increasing fasting serum trigl ycerides over time 
ultimately  reaching the threshold of  800mg/dL ( 9mmol/L ) –refer to Appendix 4for 
additional guidance .
Note : In both cases of pre -identified laboratory  thresholds listed above, 
1additional unplanned assessment may  be warranted before permanent 
withdrawal if the threshold is observed to be met as an isolated occurrence 
relative to all prior results and subject is as ymptomatic. 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 353.3.Considerations for Pausing or Stopping Treatment Arm or Trial Based on 
Observed Safety
A monthly  blinded safety review, including laboratory  values, vital signs, adv erse events and 
SAEs will be conducted throughout the study .When approximately  50% of the planned 
number of subjects are randomized, the subsequent monthly  safet y review will assess 
whether either of the below conditions are met.
More than 25% of subject s, develop a moderate or severe AE in the same system 
organ class (SOC); 
More than 25% of subjects meet the individual permanent discontinuation of dosing 
rules ( Section 3.2).
If neither of t hese criteria is met the study  will continue as planned, while continuing 
monthly  blinded safet y monitoring. If either criterion is met, an unblinded review b y a 
pre-specified Internal Review Committee (IRC), independent from the study  team, will be 
trigg ered. Based on their unblinded safet
y review the I RC will make a recommendation to 
the team to either continue the trial as designed, discontinue one or more of the active arms 
of the study , or stop the trial altogether.
4.SUBJECT ELIGIBILITY CRITERIA
This study  can fulfill its objectives only  if appropriate subjects are enrolled.  The following 
eligibility  criteria are designed to select subjects for whom participation in the study  is 
considered appropriate.  All relevant medical and nonmedical conditions s hould be taken into 
consideration when deciding whether a particular subject is suitable for this protocol. 
Subject eligibility should be reviewed and documented by  an appropriate member of the 
investigator’s stud y team before subjects are included in the study . 
4.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into 
the study :
1.Evidence of a personally  signed and dated informed consent document indicating that 
the subject has been informed of all pe rtinent aspects of the study .
2. Willing and able to comply  with scheduled visits, treatment plan, laboratory tests , and 
other study  procedures .
3.Male subjects or female subjects of non
-childbearing potential between the ages of 
18and 70 years, inclusive, at Screen 1.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 36Female subjects of non -childbearing potential must meet at least 1 of the following 
criteria:
a.Achieved postmenopausal status, defined as follows: cessation of regular menses 
for at least 12 consecutive months with no alternative pathological or 
physiological cause; status should be confirmed with a serum follicle -stimulating 
hormone (FSH) level confirming the postmenopausal state;
b.Have undergone a documented hy sterectomy  and/or bilateral oophorectomy ; 
c.Have medically  confirmed ovarian failure. 
All other female subjects (including female subjects with tubal ligations) are 
considered to be of childbearing potential. 
4. At Screen 1(Visit 1), total body  weight of >50 kg (110 lbs) and a BMI 25kg/m2.
5.Subjects a t Screen 1(Visit 1), with a medical diagnosis of Ty pe2 Diabetes Mellitus 
(T2DM )being 
treated with no more than 1 acceptable oral antidiabetic drug (see
Section 5.8.1 for acceptable versus prohibited medications ); 
OR
Subjects without a diagnosis of T2DM that meet  2of the following 5 criteria 
commonly  associated with metabolic syndrome :
Fasting Plasma Glucose (FPG)  100 mg/dL (5.6 mmol/L);
Documentation of at least stage 1 hypertension as demonstrated by a seated blood 
pressure ( BP)130/80 mmHg or medical history  of hy pertension actively  treated 
with pharmacological agents;
Fasting serum HDL -C <40 mg/dL (1 mmol/L) for males and <50 mg/dL 
(1.3mmol/L ) for females, or on pharmacological agents with explicit purpose to 
increase HDL- C (refer to Section 5.8.3 for acceptable versus prohibited 
medications);
Fasting serum trigl yceride (TG) 150mg/dL (1.7 mmol/L), oron 
pharmacological agents with explicit purpose to decrease TG (refer to
Section 5.8.3 for acceptable versus prohibited medications);
Waist circumference 40inches (102 cm) for males and  35inches (89 cm) for 
females.
Note: For laboratory  parameters, results must be as assessed by  the 
sponsor- identified central laboratory , with a single repeat permitted to assess 
eligibility , if needed, at each of these 2 visits .

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 376.At Screen 1(Visit 1), a CAP280dB/m via FibroScanassessment .
7.At Screen 2(Visit 2)
, a CAP280dB/m via FibroScanassessmen t :
Note (for #6 and #7) : if the CAPvalue is in the range of 260-279 dB/m during 
Screen 1 or Screen 2, the FibroScanassessment may  be repeated on a different 
day following at least a 4 -hour fast; thus 2
assessments (at least 1 of Screen 1 and 
repeat Sc reen 1, plus at least 1 of Screen 2 and repeat Screen 2) are required to be 
met above threshold before progressing to Screen 3.
8.At Sc reen 3(Visit 3), liver fat 8% measured by  MRI -PDFF acquisition protocol at 
the Sponsor -qualified Imaging facility , confir med via a single repeat, if deemed 
necessary  by the Sponsor -identified central imaging vendor .
4.2.
Exclusion Criteria
Subjects with any  of the following characteristics/conditions will not be included (or 
randomized) in the study :
1.Subjects with acute or chron ic medical or ps ychiatric condition including recent 
(within the past y ear) or active suicidal ideation or behavior or laboratory  abnormality  
that may  increase the risk associated with study
 participation or investigational 
product administration or may  interfere with the interpretation of study  results and, in 
the judgment of the investigator, would make the subject inappropriate for entry  into 
this study .
2.Subjects with any  of the following clinical laboratory  abnormalities at Screen 1
(Visit 1) , as assess ed by sponsor -identified central laboratory  and confirmed by  a 
single repeat, if deemed necessary :
Fasting TG >400 mg/dL;
Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or gamma 
glutam yl transferase (GGT) >2.0x upper limit of normal (ULN);
Hemoglobin A1c ( HbA1c )>7.0% ;
Fasting plasma glucose >270 mg/dL (15.0 mmol/L);
Total bilirubin >1.5x ULN with a direct bilirubin ULN;
Note : Subjects with a history  of Gilbert s yndrome will be eligible for th is 
study  provided direct bilirubin level is ULN plus AL T me etsinclusion 
criteria and alkaline phosphatase, hemoglobin, and reticulocy te count are 
ULN.
Albumin < lower limit of normal (LLN) ;

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 38Platelet count <0.95 x LLN;
International normalized ratio (INR)  1.3.
Note : For ALT, AST, total bilirub in and INR ,laboratory  values should not 
meet exclusion criteria at both Screen 1 and at Visit 4. 
3.A positive urine testfor illicit drugs at Screen 1 (Visit 1), start of Run -in (Visit 4), or 
baseline (Visit 6)
.
Note : Subjects who have been medically  presc ribed opiates/opioids or 
benzodiazepines and report the use of these drugs to the investigator at Screen 1 
may be allowed to participate if approved by  the sponsor .
4.History  of regular alcohol consumption exceeding 14 drinks/week for female subjects 
or 21 drinks/week for male subjects (1 drink = 5 ounces [150 mL] of wine or 
12
ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within the previous 
6months from Screen 1(Visit 1).
5.At Screen 1 (Visit 1), seated systolic blood pressure (BP) 160mmHg and/or 
diastolic BP 100mmHg after  5minutes of rest .
If needed, the BP may  be repeated 2 more times and the average of the 3 BP 
values will be used to determine the subject’s eligibility .
6.At Screen 1(Visit 1), supine 12-lead ECG demonstrating a correc ted QT (QTc F) 
interval >450 msec or a QRS interval >120 msec .
If QTc Fexceeds 450 msec, or QRS exceeds 120
msec, the ECG should be 
repeated 2 more times and the average of the 3 QTcFor QRS values should be 
used to determine the subject’s eligibility . 
7. At Screen 1(Visit 1), subjects with an estimated GFR <60 mL/min/1.73m2as 
calculated b y the modification of diet in renal disease equation (MDRD), and 
confirmed via a single repeat, if necessary .
8.Evidence or diagnosis of other forms of chronic liver disease, including but not 
limited to the entities listed below; evidence may  include laboratory  tests, as assessed 
by the Sponsor -identified central laboratory , with a single repeat prior to Screen 3, 
permitted to assess eligibility , if needed .
Hepatitis B virus (HBV), defined by  presence of hepatitis B surface antigen 
(HepBsAg) or hepatitis B core Antibod y (HepBcAb) ;
Hepatitis C vir us (HCV), defined by presence of hepatitis C antibody  (HCVAb);

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 39irrespective of HCV RNA (when reflexed based on a positive result for 
HCVA b).
Human Immunodeficiency  Virus (HIV) infection, defined as presence of HIV 
antibody ;
Known diagnosis of primary  biliary  cirrhosis, primary  sclerosing cholangitis, 
autoimmune hepatitis, or overlap s yndrome ;
History  of esophageal varices, ascites, or hepatic encephalopath y;
Alcoholic liver disease ;
Wilson’s disease, defined as ceruloplasmin level < LLN ;
Known diagnosis of hemochromatosis;

-1-antitry psin (A1AT) deficiency , defined as A1AT level < LLN ;
Prior known drug -induced liver injury ;
Known or suspected hepatocellular carcinoma or other liver cancer ;
History  of liver transplant, current placement on a liver transplant list, or current 
model of end- stage liver disease (MELD) score >12;
Histological presence of cirrhosis on prior biops y.
9.Subjects with any of the following medical conditions:
Any condition possibly  affecting drug absorption (eg prior bariatric surgery , 
gastrectom y, ileal resection) ;
Diagnosis of t ype 1 diabetes mellitus ;
Recent (ie within the previous 6 months) history  of congestive hea rt failure 
(New York Heart Association, NYHA, class III or IV) or unstable angina ;
A history of m yocardial infarction, stroke, ortransient ischemic attack, in the 
previous 6 months of Screen 1;
Any malignancy  not considered cured (except basal cell carcin oma and squamous 
cell 
carcinoma of the skin); a subject is considered cured if there has been no 
evidence of cancer recurrence in the previous 5 years;
Active placement of medical devices in/on thoracic or abdominal cavities such as 
pacemakers, defibrillators as these could interfere with the use of FibroScan.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 4010.Subjects with any anatomical or pathological abnormality  that would either preclude 
or tend to confound the analy sis of study  data, including an y clinically  significant 
abnormal findings on MRI -PDFF obtained at Screen 3 (Visit 3 ), by the 
Sponsor -identified central imaging vendor or subjects meeting criteria for 
contraindication for MRI -PDFF , including the following:
History  of severe claustrophobia impacting ability  to perform MRI -PDFF during 
the stud y despite mild sedation/treatment with an anxioly tic;
Subjects with metal implants, devices, paramagnetic objects contained within the 
body , and excessive 
ormetal -containing tattoos;
Subjects unable to lie still within the environment of the MRI  scanner ormaintain 
a breath hold for the required period to acquire images despite mild 
sedation/treatment with an anxioly tic;
Subjects with abdominal girth greater than the bore size of the site’s MRI  system , 
as measured b y the Hula -hoop test.
11.
Blood donation (exc luding plasma donations) of approximately  1pint (500 mL) or 
more within 60 days prior to dosing and until the on -site Follow up visit .
12. Subjects taking prohibited concomitant medication(s) or those unwilling/unable to 
switch to permitted concomitant medica tion(s) (refer to Section 5.8.).
13.Weight loss of 5% w ithin 1 month prior to Screen 1.
14.Unwilling or unable 
tocomply  with the criteria in the Lifestyle Requirements section 
of this protocol .
15. Pregnant female subjects; breastfeeding female subjects; female subjects of 
childbearing potential; f ertile male subjects who are unwi lling or unable to use highl y 
effective method (s) of contraception as outlined in this protocol (Section 4.4.4) for 
the duration of the stud y and for at least 28 days after the 
last dose of investigational 
product .
16.Investigator site staff members directl y involved in the conduct of the study and their 
family  members, site staff membe rs otherwise supervised by  the investigator, or 
subjects who are Pfizer employ ees, including their family  members, directly  involved 
in the conduct of the study .
17.Treatment with an investigational drug within 30 days (or as determined by  the local 
requireme nt) or 5 half-lives preceding the first d ose of IP (whichever is longer).
18.Subjects with known prior participation in a clinical trial involving PF- 05221304 
and/or PF -06865571 (ie received at least 1 dose of I P).

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 414.3. Randomization Criteria
On Day 1, interactive response technology (IRT) will be used to assign each eligible subject 
a randomization number, with this number recorded on the electronic Case Report Form 
(CRF).  A computer -generated randomization code using the method of random permuted 
blocks will be utilized to randomize subjects in 1:2: 2:2 ratio
(placebo:PF -05221304:PF -06865571:PF -05221304 plus PF -06865571 combination) prior to 
the first dose of IP, provided subjects satisfy  allof the eligibility  criteria outlined in
Section 4.1 andSection 4.2.
An attempt will be made to equally  balance the number of subjects assigned to each 
treatment arm within stratum by  utilizing a stra
tification scheme as follows.  Subjects 
will be stratified at randomization (Day 1) by the MRI -PDFF liver fat measurement 
determined b y the Sponsor -identified central imaging vendor of images obtained 
during Screen 3:
Screening liver fat 8% and<15%;
Screening liver fat  15%;
Subjects will then be stratified by  the presence or absence of T2DM.
4.4.Lifestyle Requirements
After confirm ation of eligibility  at Screen 3 (Visit 3)and starting at Run -in (Visit 4), subjects 
will be instructed to maintain the guidelin es described below for the duration of participation 
in the study .  These guidelines must be reiterated on Day 1 (Visit 6)and during site visits 
thereafter .  The following guidelines are provided.
4.4.1.
Meals and Dietary Restrictions
Subjects must abstain from all food and drink (except water) for at least 8, but 
preferabl y 10 hours, prior to any  blood sample collections for clinical laboratory  tests .
Note : Subjects must abstain from all food and drink (except water) for 4hours 
prior to ALL liver fat assessme nts, including Screen 1 and Screen 2.
Blinded IPs should be administered twice dail y with morning and evening meals and 
should be separated b y at least 8 hours .
Subjects will be instructed to maintain their normal diet throughout participation in 
the study (ie through Visit 11).
4.4.2.
Alcohol, Caffeine, and Tobacco
Intake of alcohol is permitted in moderation as defined in Section 4.2.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 42Consumption of caffeinated drinks and nicotine -containing products is permitted 
during p articipation in the study ; however, there may  be a need for brief interruption 
while at the site and/or Imaging facility , depending on local policy .
4.4.3. Physical Activity
Subjects will beasked to notengage in ph ysically strenuous exercise (for example: 
heav ylifting, weight training, calisthenics, and aerobics) within 48 hours before 
blood sample collections for clinical laboratory  tests.
4.4.4. Contraception
All fertile male subjects who are, in the opinion of the investigator, sexually active and at risk 
for preg nancy  with their partner(s) must agree to use a highly  effective method of 
contraception consistently and correctl y for the duration of the active treatment period and 
for at least 28 days after the last dose of investigational product.  The investigator o r his or 
her designee, in consultation with the subject, will confirm that the subject has selected an 
appropriate method of contraception for the individual subject and his partner(s) from the 
permitted list of contraception methods (see below) and will c onfirm that the subject has 
been instructed in its consistent and correct use.  At time points indicated in the Schedule of 
Activities, the investigator or designee will inform the subject of the need to use highl y 
effective contraception consistently  and correctly  and document the conversation and the 
subject’s affirmation in the subject’s chart (subjects need to affirm their consistent and 
correct use of at least 1 of the selected methods of contraception).  In addition, the
investigator or designee will instruct the subject to call immediately  if the selected 
contraception method is discontinued or if pregnancy  is known or suspected in the subject or 
partner. 
Highl y effective methods of contraception are those that, alone o r in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie, perfect use) and 
include the following:
1.Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, in serted, injected, implanted, transdermal), provided the subject or 
male subject’s female partner plans to remain on the same treatment throughout the 
entire study  and has been using that hormonal contraceptive for an adequate period of 
time to ensure effec tiveness;
2.Correctly placed copper -containing intrauterine device (IUD) ;
3.Male condom or female condom used WI TH a separate spermicide product (ie, foam, 
gel, film, cream, or suppository ). For countries where spermicide is not available or 
condom plus spermicide is not accepted as highl y effective contraception, this option 
is not appropriate;
4.Male sterilization with absence of sperm in the post vasectomy  ejaculate;

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 435.Bilateral tubal ligation/bilateral salpingectom y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accordance with the device’s label).
NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heterosexual intercourse (including during the entire period of risk associated with the stu dy 
treatments) may  obviate the need for contraception ONLY if this is the preferred and usual 
lifesty le of the subject.
All sexually  active male subjects must agree to prevent potential transfer to and exposure of 
female partner(s) to drug through ejaculat e by using a condom consistently and correctl y, 
beginning with the dose of investigational product (Day 1) and continuing for at least 28 days 
after the dose of IP(s).
4.5.Sponsor ’sQualified Medical Personnel
The contact information for the sponsor's appropri ately  qualified medical personnel for the 
study  is documented in the study  contact list located in thesupporting study  documentation. 
To facilitate access to appropriatel y qualified medical personnel on stud y
-related medical 
questions or problems, subjec ts are provided with a contact card.  The contact card contains, 
at a minimum, protocol and investigational product identifiers, subject study numbers, 
contact information for the investigat orsite, and contact details for a contact center in the 
event tha t the investigat orsite staff cannot be reached to provide advice on a medical 
question or problem originating from another healthcare professional not involved in the 
subject’s participation in the study .The contact number can also be used by  investiga t
or
staff if they  are seeking advice on medical questions or problems; however, it should be used
only in the event that the established communication pathway s between the investigator site 
and the study  team are not available. It is therefore intended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team for 
advice on medical questions or problems that may arise during the stud y.  The contact 
number is not intended for use b y the subject direct ly, and if a subject calls that number, he 
or she will be directed back to the investigat orsite.
5.STUDY TREATMENTS
For the purposes of this study , and per International Conference on Harmoni s ation ( ICH)
guidelines ,investigational product is defined as a pharmaceutical form of an active 
ingredient or placebo being tested or used as a reference /comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approv ed form, or when used for an unapproved 
indication, or when used to gain further information about an approved use (ICH E6 1.33) .
For this study , the investigational product(s) are PF -05221304 and PF -06865571 and their 
matching placebo .  These will be adm inistered as oral tablets .

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 445.1.Allocation to Treatment
Allocation of subjects to treatment groups will proceed through the use of an interactive 
response technology  (IRT) system.  The site personnel (study  coordinator or specified 
designee) will be required to
enter or select information including but not limited to the 
user’s identification ( ID)and password, the protocol number ,andthe subject number.  The 
site personnel will then be provided with a randomization number and dispensable unit (DU) 
or container number.   The I RT s ystem will provide a confirmation report containing the 
subject number , randomization number ,
and DU or container number assigned.  The 
confirmation report must be stored in the site’s files. The stud y
-specific IRT reference 
manual will provide the contact information and further details on the use of the I RTsystem . 
Table 6. Study Treatment Regimen and Dispensing Schedule
Treatm ent 
GroupTreatm ent RegimenDosagea
AM and PM
APlacebo (PF -05221304) BID
Placebo (P F-06865571) BID3 x Placebo (PF -05221304) tablets
PLUS
3 x Placebo (PF -06865571) tablets
B15 mg PF- 05221304 BID
Placebo (PF -06865571) BID3 x 5 mg PF-05221304 tablets
PLUS
3 x Placebo (PF -06865571) tablets
CPlacebo (PF -05221304) BID
300 mg PF -06865571 BID3 x Placebo (PF -05221304) tablets
PLUS
3 x 100 mg PF-06865571 tablets
D15 mg PF -05221304 BID
300 mg PF -06865571 BID3 x 5 mg PF-05221304 tablets
PLUS
3 x 100 mg PF-06865571 tablets
a: Dosing in AM (w ith breakfast) and PM (with dinner) w ill be same
A computer generated randomization schedule will be used to assign approximately  
98 subjects to one of the 4 treatment groups described in Table 6in a randomization ratio of 
1:2:2:2 for treatment groups A, B, C, and D respectivel y.  The randomization number will be 
recorded in the case report form (CRF).  The subject will receive the appropriate IPassigned 
by the IRT s ystem.
In order to maintain the double- blind design:
5mgPF-05221304 and matching placebo tablets will be the sa me size and shape ; 
similarly , 100 mg PF -06865571 and matching placebo tablets will be the same size 
and shape.
Each dose will consist of 6 white to off -white tablets representing 
PF-05221304/PF -06865571/placebo .
Note: For Visit 4(Day  -14) drug product dispensed will only  consist of 
single -blind placebo to match PF -05221304 and PF -06865571 tablets.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 455.2.Breaking the Blind
The study  will be subject and investigator blinded.
At the initiation of the study , the 
investigator site will be instructed on the method fo r 
breaking the blind.  The method will be an electronic process.  Blinding codes should be 
broken only in exceptional circumstances when knowledge of the actual treatment code is 
absolutely  essential for further management of the subject. Investigators are encouraged to 
discuss with a member of the study  team if they  believe that unblinding is necessary . When 
the blinding code is broken, the reason must be fully  documented and entered on the case 
report form (CRF) .
5.3.Subject Compliance
Compliance of single -blind placebo administration during th e Run- in period will be assessed
by pill count on Day 1 (Visit 6 ) for the purposes of inclusion into the study.   Acceptable 
compliance will be defined as self -admin
istration by  the subjects of:
  85% of the study -suppli ed blinded placebo taken by  the subject during the R un-In 
period (ie ,Visit 4to Visit 6) – up to 4single doses are permitted to be missed.
Compliance of IPadministration will be assessed during the treatment phase of the study  by 
the number of tablets r eturned by  the subjects at Visit s 7, 8, 9 and 10.
Acompliance rate of 80% with self -administration of the IPis expecte d from Day 1 
(Visit 6) to Day 42
(Visit 10); investigators must closely  monitor non -compliant 
subjects in order to enhance their adhere nce to the study  treatment.   Subjects having 
missed more than 2
-4doses of IPduring a one week treatment period will be 
re-educated on the importance of compliance on their site visit .  If similar 
non-compliance is not ed on the irnext site visit also, the subject may be discontinued 
from the study , upon discussion with the Sponsor. 
5.4. Investigational Product Supplies
5.4.1. Dosage Form(s) and Packaging
Blinded investigational products (5 mg PF-05221304, 100 mg PF -06865571 or their 
matching placebos) will be provide d as white to off -white tablets for oral administration.   All 
investigational product
swill be provided in blister packs and labeled according to local 
regulatory  requirements.   PF-05221304, PF -06865571, and their matching placebos for 
dispensation at the visits denoted in the Schedule of Activities will be packaged with blister 
pack scontaining a sufficient number of tablets to permit dosing for 14(+2) days.
5.4.2. Preparation and Dispensing
The investigational product will be dispensed using an IRT drug management sy stem from 
Visit 4to Visit 9 [refer to Schedule of Activities] .  A qualified staff member will dispense the 
investigational product via unique container numbers on the blister packs provided, in
quantities appropriate for the study  visit schedule.  Subjects should be instructed to 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 46maintain the IP in the blister pack(s) provided throughout the course of dosing at the 
labelled storage conditions and return with the dispensed blister pack(s) to the site at each 
visit starting at Visit 6(Day 1) and through morning of Visit 10 (Day 42).  The instructions 
for dosing will be provided to the sites and individual subjects.   The number of blister packs 
dispensed and the number of tablets administered per d ose will be identical for all 
randomized arms .
5.5.Administration
Subjects will be instructed to take the blinded investigational product at the same time of day , 
twice a day , with the morning and evening meals each day except for Day 42 dose, for which 
subjec ts would not take evening dose .  In addition, subjects will be instructed to delay  the 
self-administration of the blinded investigational product as well as other allowed, 
concomitant medication, if applicable, on the day
s of their outpatient visit to the site; on 
these day s, these medications will be administered at the site with the morning meal .
Subjects will swallow the investigational product whole with approximately  240 mL of 
non-carbonated water , and will not manipulate or chew the investigational pr oduct prior to 
swallowing.
Subjects will be provide d dosing instructions 
starting at Visit 4(Day  -14) to aid in 
remembering the correct steps to self
-administer blinded investigational product.
5.6. Investigational Product Storage 
The investigator o r an appro ved representative, eg , pharmacist, will ensure that all 
investigational products are stored in a secured area with controlled access under required 
storage conditions and in accordance with applicable regulatory  requirements .
Investigational product sshould be stored in their original container sand in accordance with 
the label s.  An y storage conditions stated in the SRSD willbe superseded by  the storage 
conditions stated on the product label.
Site sy stems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, refrigerated ,and/or room -temperature products).  This should 
be captured from the time of investigational product r eceipt throughout the study .  Even for 
continuous
-monitoring sy stems, a log or site procedure that ensures active evaluation for 
excursions should be available .  The intent is to ensure that the minimum and maximum 
temperature is checked each business day  to confirm that no excursion occurred since the last 
evaluation and to provide the site with the capability  to store or view the minimum/maximum 
temperature for all non
-working day s upon return to normal operations.  The operation of the 
temperature monitoring device and storage unit (for example, refrigerator), as applicable, 
should be regularl y inspected to ensure they are 
maintained in working order. 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 47Any excursions from the product label (s)storage conditions should be reported to Pfizer 
upon discovery .The site should actively  pursue options for returning the product to the
storage conditions described in the labeling , as soon as possible.  Deviations from the storage 
requirements, including any  actions taken, must be documented and reported to Pfizer .
Once an excursion is identified, the investigational product (s)must be quarantined and not 
used until Pfizer provides permission to use the investigational product (s).  It will not be 
considered a protocol deviation if Pfizer approves the use of the inv estigational product after 
the temperature excursion.  Use of the investigational product prior to Pfizer approval will be 
considered a protocol deviation. Specific details regarding information the site should report 
for each excursion will be provided to the site.
Receipt of materials, door opening and closing, and other routine handling operations where 
the products are briefl y out of thetemperature range described in the labeling are not 
considered excursions.
Site staff will instruct subjects on the proper storage requirements for take home 
investigational products .  The site staff should refer to the Investigational Product Manual for 
additional guidance on storage conditions and actions to be taken when conditions are 
outside of the specified range.
5.7.
Investigational Product Accountability 
The investiga torsite must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product(s) supplies.   All investigational products will 
be accounted for using a drug accountability  form/record .
All b lister packs of study drug must be returned to the investigator b y the subject at every  
visit and at the end of the trial, except onDay 5 visit (Visit 7), when the subject will bring the 
un-used study  drug to the sit e for compliance check, but will take it back with them to 
complete dosing for remainder of the day s, until their next site visit . 
5.7.1. Destruction of Investigational Product 
Supplies
The sponsor or designee will provide guidance on the destruction of un used i nvestigational 
product(s) (eg, at the site). If destruction is authorized to take place at the investigator site, 
the investigator must ensure that the materials are destroyed in compliance with applicable 
environmental regulations, institutional policy , and any  special instructions provided by  
Pfizer ,and all destruction must be adequatel y documented.
For all b lister packs returned to the investigator b y the subject, the investigator will maintain 
the returned suppl y until destruction is authorized. Pfizer will provide instructions as to the 
disposition of any  unused investigational product.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 485.8.Concomitant Treatment(s)
Subjects in this study  will be allowed to take certain concomitant medications to treat 
coexisting conditions such as type2 diabetes, hy perlipidemia and h ypertension.  All 
concomitant treatments taken during the stud y must be recorded with indication, daily  dose, 
and start and stop dates of administration.  Attempts must be made to notalter the doses and 
regimens of chronic background medicat ions after randomization and for the duration of 
participation in this study .  Any  changes made to background medications must be captured 
in the CRF.  All subjects will be questioned about concomitant treatment at each stud y visit.
Treatments taken within 42 days before the first dose of IP(s) on Day 1 will be documented 
as a prior treatment.  Treatments taken after the first dose of IP(s) will be documented as 
concomitant treatments.
5.8.1. Medications for Glycemic Control
Subjects with a diagnosis of T2DM are permitted to be on stable doses of 1 oral agent for 
glycemic control, starting at 8weeks prior to Visit 1(Screen 1)and until Visit 11(on-site 
Follow -up), including (but not limited to) the following approved classes of agents:
Sulphony lureas such as gl imepiride, glipizide, gl yburide;
Dipeptidy l peptidase-4 inhibitors (DPP -4i) such as sitagliptin, saxagliptin, 
vildagliptin;
Meglitinide ssuch as repaglinide, nateglinide .
The use of the following classes of agents is NOT permitted starting at 8weeks prior to 
Visit 1and until Visit 11 (on -site Follow- up):
Metformin ;
Thiazolidinediones ( TZDs ) such as pioglitazone and rosiglitazone;
Subcutaneously  administered agents for gl ycemic control (eg, insulin, exenatide, 
liraglutide, pramlintide);
Sodium -glucose co -transporter 2 (SGLT2) inhibitors such as canagliflozin, 
dapagliflozin, empagliflozin .
5.8.2. Anti -Hypertensive Medications
Use of background antihy pertensive agent(s) is permitted .  Doses of antihy pertensive agents 
should be stable for at least 8weeks prior to Screen 1and throughout the study  (until on- site 
Follow -up visit, Visit 11). 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 495.8.3. Lipid -Modifying Medications
Subjects are permitted to be on stable doses of the following lipid -modify ing agents, starting 
at 8weeks prior to Screen 1 and until on- site Follow -up visit, including (but not limited to) 
the following: 
Statins such as atorvastatin, simvastatin , pitavastatin, pravastatin;
Note :Rosuvastatin , gemfibrozil and fluvastatin are notpermitted within 4weeks
prior to Screen 1 and until on-site Follow-up vi sit;
Bile acid sequestrants such as cholest yramine, colestipol, colesevalam;
Fenofibrate;
Nicotinic acid/niacin.
5.8.4. Other Acceptable Concomitant Medications
Subjects on the following list of medications must be on stable doses (ie, at least 8 weeks 
prior to S creen 1) and for the duration of participation in the study  through on -site Follow-up 
visit:
Inhaled and topical corticosteroids;
Thyroid replacement therapy ;
Postmenopausal hormone therap y;
Non-steroidal anti -inflammatory  medications (NSAIDs) such as ibup rofen, 
ketoprofen, naproxen, indomethacin, and meloxicam.  I ntermittent use of these 
medications is also permitted;
Intermittent use of acetaminophen/paracetamol at doses 1gram per day ;
Aspirin at doses  325mg per day ;
Antidepressant medications such as tricyclic agents, selective serotonin reuptake 
inhibitors, and serotonin/norepinephrine reuptake inhibitors;
Certain herbal supplements but only following consultation with Sponsor;
Limited use of nonprescription medications that are not believed to affec t subject 
safet y or the overall results of the study may be permitted on a case -by-case basis 
following approval b y the sponsor.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 505.8.5. Prohibited Concomitant Medications
Subjects must abstain from using the following medications for 4weeks prior to Screen 1
and until on - site Follow- up visit:
Chronic use of s ystemic glucocorticoids such as prednisone, dexamethasone, 
triamcinolone, budesonide, betamethasone; and immunosuppressants such as 
tacrolimus;
Pharmacological agents with approved indication for weight loss such as orlistat and 
sibutramine; 
Over -the-counter appetite -simulant or appetite- suppressant, as advertised; 
(Medical -grade) marijuana, regardless of medical indication;
Specific classes of agents given that the current study  is the first study  for 
admi nistration of combination I Ps, in a patient population:
Coumadin- type anticoagulants orother anticoagulants (eg, dabigatran); 
Anticonvulsants;
Antiarrh ythmics, except for beta blockers or calcium channel blockers if used for 
the management of conditions other than arrh ythmias.
Medications historically  associated with fatt y liver are prohibited if used for 
4weeks of continuous use in the previous 12 months prior to Screen 1, examples 
include: 
Amiodarone, methotrexate, tetracy clines, tamoxifen, estrogens at doses greater 
than those used for hormone replacement, anabolic steroids, valproic acid, other 
known hepatotoxins .
Strong inducers and inhibitors of CYP3A enzy me (see Appendix 2);
Note:short term use of pot ent CYP3A inhibitors (eg, ketoconazole, itraconazole) 
for management of fungal infections  4-weeks prior to Visit 1 (Screen 1)is 
acceptable but use must be avoided post randomization .
Sensitive 
breast cancer resistance protein (BCRP )and P-glycoprotein ( P-gp)
substrates (eg, rosuvastatin and digoxin);
CYP2C9 substrates (eg, fluvastatin, diclofenac, celecoxib, torsemide) ;
Use of chronic agents which are potent inducers of CYP3A (eg, rifampin);

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 51Use of CYP3A4/5 substrates with narrow therapeutic index –eg, alfentanil, 
astemizole, cisapride, cyclosporine, dihy droergotamine, ergotamine, fentany l, 
pimozide, quinidine, sirolimus, tacrolimus, and terfenadine;
Use of chronic agents which are clinically  significant organic anion transporter 
polypeptide ( OATP )inhib itors (eg, cy closporine, gemfibrozil, rifampin).
5.9.Rescue Medication
There is no rescue therapy to reverse AEs observed with administration of IP (s); standard 
medical supportive care should be provided to manage the AEs. 
6. STUDY PROCEDURES 
A signed and dated Informed Consent Document ( ICD)will be obtained from each subject at 
Visit 1 (Screen 1) before performing any  protocol -specific procedures.  All requirements and 
procedures of the trial will be thoroughly reviewed with all subjects.  The results of the 
clinical laboratory  assessments and all screening procedures will be evaluated with respect to 
inclusion and exclusion criteria to determine the subject’s eligibility .  If a subject does not 
qualify  for the trial, he or she will be considered a screen failu re.  Adverse Event (AE) 
reporting, including Serious Adverse Event (SAE) reporting will begin from the time 
the ICD is signed at Visit 1 (Screen 1). 
For the procedures described below, where multiple procedures are scheduled at the same 
time points relati ve to dosing, the following chronology  of events should be adhered to as 
much as possible: 
12-lead ECG :obtain prior to vital signs assessment, blood samples, and prior to 
dosing ;
Vital Signs (BP, pulse rate) :obtain after 12 -lead ECG collection but prior to 
obtaining blood samples and prior to dosing;
Fasting blood samples, including pre-dose PK: after assessment of 12 -
lead ECG and 
vital signs but prior to dosing;
Other pre -dose procedures :should be obtained/performed as close as possible to the 
schedule d time, but may  be obtained before or after blood specimen collection;
Dosing of blinded IP (s):must occur after any pre -dose blood sample collections.
6.1.Screening
Refer to the Schedule of Activities for the study  procedures to be completed at the Screening 
visits.  The 3screening visits are to be performed sequentially . 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 52At Screen 1, subjects will be consented and all screening procedures (except liver fat 
assessment by  2ndFibroScan and by  MRI -PDFF) undertaken to determine el igibility  –
refer to Section
4.1andSection 4.2;
Only after subjects are identified to be otherwise eligible, should they proceed with 
Screen 2 for another FibroScanassess ment as performed at Screen 1;
Following confirmation of liver fat content at Screen 2, subjects should proceed to 
the Imaging center for the Screen 3 visit to undergo liver fat assessment via 
MRI -PDFF acquisition to assess whether they  meet inclusion crit erion 8,Section 4.1.
For Visit 1, subjects will be instructed to arrive at the study  site after at least an 8
-hour, but 
preferabl y 10-hour fast (except water).   For Visit s 2and 3 , fast ing (water allowed) for 
4hours is required. 
Subjects will be screened within 56days (including 14 days of single -blind Run
-In period) 
prior to the first dose of the blinded I P to confirm that they  meet the subject selection criteria 
for the stud y.  The duration between Screen 1 (Visit 1) and start of Run -In period (Visit 4) 
should be 
at least 28 days, but should not exceed 42 days. In rare cases, subjects may  be 
re-screened; however, this is permitted only when, due to logistical constraints , the 
maximu m period between the Screen 1 and Day 1 of 72days is exceeded.  In such cases, all 
screening procedures must be repeated and the subject assigned a new 8 -digit single subject 
identifier ( SSID
)number.  Subjects must be deemed to meet all the eligibility  criteria 
including assessment of liver fat via MRI- PDFF at Screen 3, under the new 8- digit SSI D.
To prepare for stud y participation, subjects will be instructed on the use of Lifestyle 
Requirements ( Section 4.4) and Concomitant Treatments ( Section 5.8).
6.2.Run-inPeriod (Visit 4
)
After the investigator has determined all eligibility criteria have been satisfied 
(approx imately  within 1week following Visit 3), subjects wi ll return to the site after a 
minimum 8 -hour, but preferabl y 10-hour fast (except water).
  The single -blind Run-in period 
will serve to familiarize the subject with the study  treatment regimen and exclude subjects 
who are not compliant with dosing.  This v isit will occur 14 2days prior to the planne d date 
of randomization (Visit 6, Day 1). 
For all subjects, refer to the Schedule of Activities for the stud y procedures to be comple ted 
at the Run
-in visit (Visit 4). 
Following completion of the above procedures, single -blind IP will be self -administered 
(with meal) 
while witnessed by  adequately  trained site staff.  Subjects will then be 
discharged from the site with enough IP to last until Day 1 (Visit 6). 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 536.3.Baseline MRI -PDFF (Vi sit 5)
Between 2 to 6days, inclusive, prior to Visit 6(Day 1), subjects will be instructed to report 
to the I maging facility following a 4-hour fast, and within  2hours of the Visit 3time to 
undergo liver fat assessment via MRI -PDFF.  Subjects should self-administer single -blind I P 
(with meal) post -MRI -PDFF.
Note: If the subjects are found to have a non -evaluable MRI -PDFF, they  may  have to 
come back to Imaging center for a single repeat assessment, preferabl y still within 
2-4days of the Day 1 visit (V isit6).
Note: Subjects will be informed via a phone call if they  are found not to meet 
eligibility  criteria of 8% liver fat .  In that case, the subjects will be discontinued.
6.4.Study Period
6.4.1. Day 1 (Visit 6
) 
Approximately 14days after Visit 4, subjects wil l return to the site after a minimum of an 
8-hour, but preferably  10 -hour fast. 
Subjects will be asked to return IP dispensed at Visit 4 for an assessment of the pill count.  
Subjects must be at least 85% compliant with the placebo run -in IP in order to b e 
randomized. 
Refer to the 
Schedule of Activities for the study procedures to be completed prior to 
administration of IP on Day 1.  Be sure to collect a genomic banked biospecimen for 
OATP genoty ping.  If missed, collect at the ne xt availa ble time point when biospecimen
are 
being collected in conjunction with a subject visit. 
Subjects who meet safet y eligibility  ie,ECG , vital s and weight , liver fat eligibility  as 
determined b y FibroScan (CAP 
280 dB /m)and MRI -PDFF (8%), compli ance criteria 
(>85% compliant) and are 
negative for urine drug test will be randomized to double -blind 
study  treatment on Day 1.  Sites will contact the IRT system for assignment of double -blind 
treatment.  Double- blind IP(s) will be dispensed to subjects via IRT and self -administered.   
Following witnessed dosing of IP(with meal) ,an approximate 2-week supply  of 
double -blind I P will be dispensed, and subjects will be discharged from the site. 
6.4.2. Day 5 (Visit 7) 
At 5 1days from Visit 6, subjects will return to the study  site after a minimum of an 8 -hour, 
but preferabl y 10-hour fast.   Subjects will bring un- used supply  of IP for compliance check.
Note: If subjects do not meet at least 80% compliance, subjects will be re -educated 
on the importance of dosing c ompliance .
Refer to the Schedule of Activities for the study  procedures to be completed prior to 
administration of I P on Day 5. 

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 54Following witnessed dosing of IP (with meal), subjects will be d ischarged from the site with 
their un-used IP, to be taken for remainder of the days until t heir next visit (Visit 8).
6.4.3. Day 14 (Visit 8) and Day 28 (Visit 9)
At 14±2 and 28 ±2 days from Visit 6, subjects will return to the study site after  a minimum of 
an 8-hour, but preferably 10-hour fast.
Refer to the Schedule of Activities for the study procedures to be completed prior to 
administration of IP(s) on Day 14 and on Day 28 respectively. 
•Note: If, during compliance check it is found that a subject is <80% compliant and if 
this is the first time they were <80% compliant in dosing, the subject will be 
re-educated about importance of compliance at these visits.  If  this is subject’s second 
time not meeting a minimum of 80% compliance requirement, the s ubject may be 
discontinued, after consultation with the Sponsor. 
Following completion of the above procedures, double-blind IP(s ) will be dispensed to 
subjects via IRT and self-administered (with meal). 
 
 
6.4.4. Day 42 (Visit 10)
Within approximately 24 hours prior to the Day 42 visit, or on the day of the Day 42 visit, 
subjects will be instructed to report to the Imaging facility fo llowing a ≥4-hour fast (if the 
visit to the Imaging facility is 24 hours prior) or a minimum of  8-hour, but preferably 
10-hour fast (if the visit to Imaging facility is on same day a s site visit ie Day 42 visit) and 
within ±2 hours of the Visit 5 time to undergo liver fat assessment via MR I-PDFF. 
Refer to the Schedule of Activities for the study procedures to be completed prior to 
administration of IP on Day 42.
Subjects should self-administer double-blind IP(s) (with meal) post-MRI-PDFF.  If subjects 
perform MRI-PDFF in the morning of same day as Visit 10 site vis it, they should wait for 
blood collections before administration of morning dose at the site. Subjects will not take 
evening dose on Day 42. 
6.4.5. Follow-up
At ≥7 days and ≤14 days following the last dose of double-blind IP(s), subjects w ill return to 
the study site for a follow-up visit after a minimum 8-hour, but  preferably 10-hour fast. 
Refer to the Schedule of Activities for the study procedures to be completed at this visit.CCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 556.4.6. Follow -up Contact
A Follow -up contact via telephone of all subjects will be completed at least 28 calendar day s, 
and up to 35 calendar days after the last administration of double
-blind I P(s). 
Refer to the Schedule of Activities for the study procedures to be completed during this 
contact.
Note :this contact can be considered as on -site in order to permit follow -up of open 
AEs and/or abnormal laboratory  tests from prior visit(s), as needed.
6.5.Subject Withdrawal /Early Termination
In this stud y, an y subject who discontinues participation in the trial any time prior to 
administration of double -blind I P(s) will have no additional procedures completed.  
However, an earl y termination visit is to be considered for all subjects who were randomized 
and received at least 1 dose of the double -blind IP(s), and then are prematurely  withdrawn 
from the study .  Subjects should return to the site for final safety  assessments to be scheduled 
as earl y as practically  feasible following the decision to withdraw but 14days after last dose 
of double -blind I P(s).  Subjects should be questioned regarding their reason for withdrawal.  
At the earl y withdrawal visit, every effort must be made to complete the assessments outlined 
in the Schedule of Activities.  Lack of c ompletion of all or any  of the early  termination 
procedures will not be viewed as protocol deviations so long as the subject’s safet y was 
preserved. 
Withdrawal of Consent
Subjects who request to discontinue receipt of study  treatment will remain in the st
udy and 
must continue to be followed for protocol specified follow- up procedures. The only  
exception to this is when a subject specificall y withdraws consent for an y further contact 
with him or her or persons previously  authorized by  the subject to provide this information.
Subjects should notify  the investigator in writing of the decision to withdraw consent from 
future follow -up, whenever possible. The withdrawal of consent should be explained in 
detail in the medical records by  the investigator, as to whether the withdrawal is only from 
further receipt of investigational product or also from study  procedures and/or posttreatment 
study  follow -
up, and entered on the appropriate CRF page. In the event that vital status 
(whether the subject is alive or de ad) is being measured, publicly  available information 
should be used to determine vital status only  as appropriatel y directed in accordance with 
local law.
Lost to F ollow -up 
All reasonable efforts must be made to locate subjects to determine and report th eir ongoing
status. This includes follow- up with persons authorized by  the subject as noted above. Lost 
tofollow -up is defined by  the inabilit y to reach the subject after a minimum of 2documented 
phone calls, faxes, or e -mails as well as lack of response b y the subject to 1registered mail 
letter. All attempts should be documented in the subject’s medical records. If it is 
determined that the subject has died, the site will use locally  permissible methods to obtain 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 56the date and cause of death. If theinvestigator’s use of a third -party representative to assist 
in the follow -up portion of the study  has been included in the subject’s informed consent, 
then the investigator may use a sponsor -retained third -party representative to assist site staff 
with o btaining the subject’s contact information or other public vital status data necessary  to 
complete the follow -up portion of the study . The site staff and representative will consult 
publicly  available sources, such as public health registries and database s, in order to obtain 
updated contact information. If,
after all attempts, the subject remains lost to follow- up, then 
the last -known- alive date as determined by  the investigator should be reported and 
documented in the subject’s medical records.
Subjects may withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn at an y time at the discretion of the investigator or sponsor for safety (see also the 
Withdrawal From the Study Due to Adverse Events section) or behavioral reasons, or the 
inability  of the subject to comply  with the protocol -required schedule of study  visits or 
procedures at a given study  site.
If a subject does not return for a scheduled visit, every  effort should be made to c ontact the 
subject.
  All attempts to contact the subject and information received during contact attempts 
must be documented in the subject’s medical record.  In an y circumstance, every  effort 
should be made to document subject outcome, if possible.  The i nvestigator should inquire 
about the reason for withdrawal, request that the subject return all unused investigational 
product(s) , request that the subject return for a final visit, if applicable, and follow up with 
the subject regarding an y unresolved 
adverse events ( AEs).
If the subject withdraws from the study , and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collected.  The sponsor may  retain and continue to use any data collected before such 
withdrawal of consent.
Subjects who withdraw from the study  may  be replaced at the discretion of the investigator 
upon consultation with the sponsor. 
7.ASSESSMENTS
Every  effort should be made to ensure that the protocol -requi red tests and procedures are 
completed as described. However ,it is anticipated that from time to time there may  be 
circumstances outside of the control of the investigator that may  make it unfeasible to 
perform the test. In these cases the investigator will take all steps necessar y to ensure the 
safet y and well -being of the subject. When a protocol -required test cannot be performed ,the 
investigator will document the reason for this and any corrective and preventive actions that 
heor she has taken to e nsure that normal processes are adhered to as soon as possible. The 
study  team will be informed of these incidents in a timely  manner .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 577.1. Imaging Assessments
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.1.2. Assessment of Liver Fat Using MRI-PDFF Acquisition and An alysis
The MRI-PDFF technique is an established method that enables qu antification of fat content 
in the liver.  Imaging data are acquired with this method in a manner that accounts for 
confounding factors that can otherwise result in inaccurate mea sures of liver fat, while also 
providing whole-liver coverage such that fat content can be ass essed across each of the 
9 Couinaud liver segments.  This noninvasive methodology has bee n found to be more 
sensitive to change in liver fat content than histologically-de termined steatosis grade, and has 
found utility in previous trials of prospective NASH therapeutic s. C
CI
CCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 58At scheduled visits (refer to the Schedule of Activities), liver fat will be assessed via MRI, 
using the PDFF acquisition protocol. 
Across the stud y sites selected for t his study , the Sponsor -identified central imaging vendor 
will train the staff at the Imaging facility  on the MRI -PDFF acquisition protocol, on 
just-in-time review of the acquired images for assessment of images being deemed evaluable, 
and on transfer (pref erably  electronically ) of the images to the Sponsor -identified central 
imaging vendor for analysis and quantification of liver fat.  Only the staff members at the 
Imaging facility who are trained by the Sponsor-identified central imaging vendor are 
permitt ed to acquire images in subjects who consent for this study, however in 
rare/limited situations, exceptions may  be granted with written approval of the Sponsor .  
Complete details on the MRI -PDFF acquisition protocol, determination of quality  of images, 
andtransmission of data to Sponsor -identified central imaging vendor will be provided in an 
Imaging Manual offered to the study  sites prior to the start of the study .
As much as practically possible , analy sis of the MRI -PDFF images acquired at or prior to 
baseline (Visit 5) and Visit 10 (Day 42) will be undertaken b y a single colleague at the 
Sponsor -
identified central imaging vendor who will be blinded to individual subject’s 
clinical data, as well as randomization and stratification assignment. 
7.1.3. Analysis of MRI -PDFF Images Including Determination of Eligibility 
A subject’s eligibility  for this study  based on liver fat as a ssessed via MRI -PDFF at Screen 3
will be made b y the Sponsor -identified central imaging vendor, only .  The study  sites will be 
informed w hether a subject meets eligibility  criteria orif the screening MRI -PDFF should be 
repeated once, as determined by  the Sponsor -identified central imaging vendor.  If the 
MRI -PDFF is non -evaluable for the 2ndtime, the subject will be screen failed.   For al l 
subsequently  scheduled MRI -PDFF assessments, study  sites will only  be informed whether 
the images are deemed evaluable (or not).
  If the MRI -PDFF images at baseline (Visit 4) 
and/or Visit 10 (Day 42or before) are found non- evaluable, the assessment may  be repeated 
once after consultation with the Sponsor.
  If the MRI -PDFF images are non -evaluable on 
single repeat also , the central imaging vendor will seek Sponsor ’s guidance on further steps.   
Sponsor may decide to have the subject re -visit the I maging ce nter for repeat MRI -PDFF or 
discontinued.  If the single repeat of MRI -PDFF is to be performed for Visit 10, it has to be 
completed prior to Day 42 visit. 
7.1.3.1. Management of Incidental 
Findings 
An incidental finding is one unknown to the subject that has pote ntial health or reproductive 
importance, which is discovered unexpectedl y in the course of a research study , but is 
unrelated to the purpose and bey ond the aims of the study .
The MRI s images will be reviewed by  the Sponsor -identified central review facilit y.The 
purpose of this review is to evaluate images for the amount of fat in the liver .  Central image 
review is not a complete medical review of the subject.
  If, during the central review process, 
an unexpected observation is identified and this finding could, in the opinion of the central 
reviewer, have a significant health or reproductive consequence, this finding may  be shared 

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 59with the study sponsor for disclosure to the principal investig ator.  All follow-up testing and 
final diagnosis will be left to the discretion of the medical p rofessionals at the site or those 
with an existing physician-patient relationship.  The principal  investigator will be responsible 
for reporting any AEs identified from incidental findings as de scribed in the ADVERSE 
EVENT REPORTING section. Identification of such incidental findings during the c entral 
review process should not be expected, and the site maintains r esponsibility for performing a 
general safety review of all images as per site protocols. 
 
 
 
7.2. Safety
7.2.1. Physical Examinations
Physical examinations may be conducted by a physician, trained physician's assistant, or 
nurse practitioner as acceptable according to local regulation.   A full physical examination 
will include head, ears, eyes, nose, mouth, skin, heart and lun g examinations, lymph nodes, 
and gastrointestinal, musculoskeletal, and neurological systems .  At screening only, physical 
exam will also include arm and waist circumference and height m easurements.  The limited 
or abbreviated physical examination will be focused on general appearance, the respiratory 
and cardiovascular systems, and subject-reported symptoms.
7.2.2. Body Weight and Hula-hoop Test
For measuring weight, a scale with appropriate range, resolutio n and calibration will be used 
and must be placed on a stable, flat surface.  Subjects must re move shoes, bulky layers of 
clothing, and jackets so that only light clothing remains.  The y must also remove the contents 
of their pockets and remain still during measurement of weight.
For hula-hoop test, subjects will be asked to be in the standin g position with arms either to 
the side or vertically up above the head, feet positioned close  together, and weight evenly 
distributed across both feet,
Using a sponsor-approved hula-hoop, an attempt will be made to slide the hoop over the 
subjects head and determine if the hoop can pass over the subje cts’ trunk and hips; 
Hula-hoop will be passed while the subject is at the end of a n ormal expiration (when lungs 
are at their residual capacity).
•If the hula-hoop slides easily from the head down to the feet, the subject is eligible 
and confirmed to fit inside the site-specific MRI machine and i ts respective bore size.
•If the hula-hoop cannot slide down to the feet (eg, fits snug a t the waist or hips), the 
subject is deemed ineligible for this study.CCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 60Note: as much as practically  possible, the sa me position of the arms must be used for 
all MRI -PDFF assessments as used for hula -hoop test .
Note: Additional details on steps for identification of the appropriate hula -hoop 
circumference, which depends on the individual Imaging facility’s MRI machine 
opening (i e,bore diameter) along with bed thickness, and coils selected, will be 
provided in an Imaging Manual offered to the sites prior to the start of the study . 
7.2.3. Blood Pressure and Pulse Rate
B
lood pressure a nd pulse rate will be measured at times specified in the Schedule of 
Activities section of this protocol.  Additional collection times, or changes to collection 
times, of BP and pulse rate will be permitted, as necessary , to ensure appropriate collection 
of safet y data.
Single, s eated BP will be measured with the subject’s arm supported at the level of the heart, 
and recorded to the nearest mmHg after approximately  5minutes of rest.  The same arm 
(preferabl y the dominant arm) will be used throughout the study.  Subjects should be 
instructed not to speak during measurements.   The assessment at Visit 6 (Day 1) will serve as 
each subject’s baseline;
The same properl y sized and calibrated BP cuff will be used to measure BP each time.  The 
use of an automated device for measu ring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery for at least 
30seconds.
7.2.4. Electrocardiogram
In this stud y, assessment of cardiac conduction via 12-lead ECGs will be collected at t he 
nominal time points specified in the Schedule of Activities per the following specifications:
All scheduled 12
-lead ECGs should be performed after the subject has rested quietly  
for 10minutes in supine position .
Single, supine 12- lead ECGs will be obtained and measurement collected prior to 
the first dose on Day 1 (Visit 6) will serve a s each subject’s baseline value .
If the QTcF value is (a) above the threshold value (ie, is  60msec from the baseline, 
or is 500msec), or (b) if post- randomization QTcF interval is increased by  
30msec from the baseline andis >450 msec, then ECG must be repeated at least 
hourly  until QTcF values from 2 successive ECGs fall below the threshold value that 
triggered the repeat measurement .
In some cases, it may  be appropriate to repeat an abnormal 12 -lead ECG to rule out improper 
lead placement as contributing to the ECG abnormality .  It is important that leads are placed 
in the same positions each time in order to achieve precise ECG recor dings.  If a 
machine -read QTcF value is prolonged, as defined above, repeat measurements may  not be 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 61necessary  if a qualified phy sician’s interpretation determines that the QTcF values are in the 
acceptable range.
7.3. Clinical Laboratory Tests 
The following cl inical laboratory  tests will be performed at times defined in the Schedule of 
Activities.  Additional laboratory  results may  be reported on these samples as a result of the 
method of anal ysis or the ty pe of anal yzer used b y the clinical laboratory; or as derived from 
calculated values.  These additional tests would not require additional collection of blood.  
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y concerns.
Table 7. Clinical Laboratory Tests
Hem atology Chemistry Urinalysis Fasting Lipid Panel
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils 
(Abs)
Eosinophils (Abs)
Monocytes (Abs)
Baso phils (Abs)
Lymphocytes (Abs)BUN/urea 
Creatinine [andeGFR 
using MDRD]a
Plasma glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
GGT
Total bile acids
Uric acid
Albumin
Total protein
Direct bilirubinb
Indirect bilirubinb
Serum cystatin C
Creatinine KinasecpH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopydTotal cholesterol, 
VLDL, 
HDL -C, 
Triglycerides
and 
direct LDL -C
Other
FSHe,g
Urine drug testf
Serology (HepB sAg, 
HepBcAb, HCVAb, HCV 
RNA, HIV)g
Ceruloplasming
Coagulationg(Plasma 
aPTT, PT, PT/INR )
1-antitrypsin (A1AT)g
Additional Tests (Needed for Hy’s Law)
AST, ALT (repeat)
Total bi lirubin (repeat)
Albumin (repeat)
Alkaline phosphatase (repeat)
Direct bilirubin
Indirect bilirubin
Creatinine kinase
GGT
PT/INR
Total bile acids
Acetaminophen drug and/or protein adduct levels

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 62a. Estimated glomerular filtration rate (eGFR) will be calculated  using the modification of diet in renal disease 
(MDRD) equation.
b. Direct and indirect bilirubin measured at Screen 1 and Visit 6 ; after initiation of investigational product, direct 
+ indirect bilirubin are measured only when total bilirubin is > ULN.
c. Test to be assessed at Screen 1 and Visit 6 only; after initiat ion of investigational product, this test measured only 
when ALT or AST is > ULN.
d. Only if urine dipstick is positive for blood, protein, nitrit es or leukocyte esterase.
e. In females, only.f. Subjects may undergo random urine drug testing at the discret ion of the investigator.  Drug testing will be 
performed using dipstick and must be negative for subjects to r eceive IP. 
g. At Screening visit only.
Abbreviations: Abs = Absolute; ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; aPTT = activated 
Partial Thromboplastin Time; BUN = Blood Urea Nitrogen; eGFR = Estimated glomerular filteration rate; 
HbA1c = glycosylated hemoglobin (NGSP certified method); MCH = Me an Corpuscular Hemoglobin; 
MCHC = Mean Corpuscular Hemoglobin Concentration; MCV = Mean Co rpuscular Volume; MDRD = Modification of 
diet in renal disease; PT = Prothrombin Time; PT/INR = Prothrom bin Time/International Normalized Ratio.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administra tion may be retained and 
stored for the duration of the study.  
 
 
7.3.1. Serum for Cystatin C
Blood samples (approximately 2.5 mL) to provide a sufficient qua ntity of serum for analysis 
of cystatin C will be collected into appropriately labeled tube s at pre-specified nominal time 
points outlined in the Schedule of Activities .  GFR will be estimated from the cystatin C 
using the Chronic Kidney Disease Epidemiology Collaboration (CK D-Epi)-Cystatin C 
equation provided below.
•For serum cystatin C (Scys) ≤0.8 mg/L:
eGFR = 133×(Scys/0.8)-0.499×0.996Age[×0.932 if female].
•For serum cystatin C (Scys) >0.8 mg/L:
eGFR = 133×(Scys/0.8)-1.328×0.996Age[×0.932 if female].
Review of Cystatin C results are not required for dosing or disc harge.
 
 
 CCICCI
PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
CCI
PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 64 
 
 
 
7.5. Pharmacodynamics Parameters
Blood samples for pharmacodynamics biomarker analysis - including  NASH-related 
biomarkers, potential mechanism-related parameters, metabolic pa rameters, and exploratory 
markers of liver function - will be collected at the nominal tim e points specified in the 
Schedule of Activities . 
•These samples must be processed and shipped as indicated in the  study-specific 
laboratory manual provided to the investigator site, prior to i nitiation of study, to 
maintain sample integrity:
•Any deviations from the sample handling procedure (eg, sample c ollection and 
processing steps, interim storage or shipping conditions), incl uding any actions 
taken, must be documented and reported to the sponsor.  On a ca se-by-case basis, 
the sponsor may make a determination as to whether sample integ rity has been 
compromised.  Any deviation from the specified sample handling procedure 
resulting in compromised sample integrity will be considered a protocol 
deviation.
•Any scheduled collection prior to next dose of blinded investig ational product, if 
undertaken post dose, will be captured as a protocol deviation e ven if results are 
deemed evaluable.
•Samples will be analyzed using a validated analytical method (w hich need not meet 
Good Laboratory Practice (GLP) standards, especially for these exploratory 
endpoints) but in all cases, the method will be in compliance w ith Pfizer standard 
operating procedures.
Refer to list of endpoints outlined in Section 2 that encompass these pharmacodynamics 
biomarkers.  As part of understanding the effects of co-adminis tration of the IP(s), samples 
may be used for evaluation of the bioanalytical method, as well  as for other internal 
exploratory purposes. C
CI
PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 657.5.1. Serum for Lipid Panel
At each time point specified in the Schedule of Activities , a sufficient volume of blood 
(approximately 3.5 mL) will be collected into appropriately labe led tubes for analysis of total 
cholesterol, HDL-C, triglycerides and direct LDL-C, with the ex ception of lipid panel 
performed at Screening, which will be completed as part of Section 7.3 . 
Total cholesterol/HDL-C ratio and non-HDL cholesterol will be d erived from the lipid panel.
 
 
 
 
 
 
 
 
7.5.3. Apolipoprotein A1, B100 and Apolipoprotein C3
At each time point specified in Schedule of Activities , approximately 4 mL of blood will be 
collected to ensure sufficient serum for analysis of apolipopro teins A1, B100 and C3.  These 
samples will be processed and shipped for analysis to the Spons or-identified laboratory.
 
 
 
 
 
 
 CCICCI
PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 66 
 
7.5.8. Plasma PCSK9
Blood samples (approximately 2 mL) to provide a sufficient quanti ty of plasma for PCSK9 
analysis will be collected into appropriately labeled tubes con taining K 2EDTA at times 
specified in the Schedule of Activities section of the protocol.  These samples will be 
processed and shipped for analysis to the Sponsor-identified la boratory.
7.6. Pharmacogenomics
7.6.1. Genotyping Analysis 
Blood samples for genotyping may be examined to assess the impa ct of allelic variants of 
drug-metabolizing enzymes and transporters.  Additionally, thes e samples may also be used 
for retrospective evaluation of additional genetic variants ass ociated with variation in 
pharmacokinetics (PKs) or to explore AEs should these be observ ed.  Samples will be 
retained for a period of up to 3 years after regulatory approva l.
A 4 mL blood sample will be collected from each subject into a p lastic dipotassium 
ethylenediaminetetraacetic acid (K 2EDTA) tube at times specified in the Schedule of 
Activities section of the protocol. 
As part of further understanding the biological response to IP,  samples will be used, at a 
minimum , for OATP genotyping.  In addition, the sample may be used for  evaluation of 
other related genotyping as well as development and validation of bioanalytical methods.  
Any data outside of the OATP genotyping will be used for intern al exploratory purposes and 
will not be included in the clinical study report (CSR).
The pharmacogenomic (PGx) samples must be processed and shipped  as indicated in the 
instructions provided to the investigator site to maintain samp le integrity.  Any deviations 
from the PGx processing steps, including any actions taken, mus t be documented and 
reported to the sponsor.  On a case-by-case basis, the sponsor may make a determination as 
to whether sample integrity has been compromised.  Any sample d eemed outside of 
established stability, or of questionable integrity, will be co nsidered a protocol deviation.
7.7. Banked Biospecimens
Banked biospecimens will be collected from subjects for explora tory research relating to the 
drug response and disease/condition under study.  These collect ions are not typically 
associated with a planned assessment described in the protocol.   They will be handled in a 
manner that protects each subject’s privacy and confidentiality .  Banked biospecimens will 
be assigned the subject’s study identification code (ID) at the  site.  The data generated from 
these banked biospecimens will also be indexed by this ID.  Bios pecimen will be kept until 
destruction in facilities with access limited to authorized per sonnel, and biospecimen-derived CCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 67data will be stored on password -protected computer sy stems.  The key  between the subject’s 
ID and the subject’s direct personall y identifying information (eg, name, address) will be 
held at the study  site.  Biospecimens will be used only  for the purposes described in the 
protocol and informed consent document; an y other uses require additional ethical approval.  
Unless a time limitation is required b y local regulations or et hical require ments, 
biospecimens will be stored for man y years (no time limit) to allow for research in the future, 
including research conducted during the length y drug -development process and also 
post-marketing research.  Subjects may  withdraw their consent for the use of their banked 
biospecimens at an y time by  making a request to the investigator; in this case, an y remaining 
biospecimens will be destroy ed, but data already generated from the biospecimen will 
continue to be available to protect the integrit y of exist ing analyses. 
Unless prohibited by  local regulations or ethics committee decision, a 2mL blood genomic 
banked biospecimen Prep D1.5(dipotassium edetic acid [ethy lenediaminetetraacetic acid] 
[K2EDTA] whole -blood collection optimized for DNA anal ysis) wil l be coll
ected prior to 
dosing at Visit 6 to be retained for potential pharmacogenomic/genomic/biomarker anal yses 
related to drug response and disease/condition under study .  For example, putative safet y 
biomarkers, drug -metabolizing enzy
me genes, drug -transport protein genes, or genes thought 
to be related to the mechanism of drug action may be examined.  The primary  purpose is to 
examine DNA; however, the biospecimen may  also be used to study  other molecules 
(eg,RNA, proteins, and metabolites).
Additiona l banked biospecimens to be retained for such exploratory  anal yses in this study  
include the following: 
Prep B1 .5(K2EDTA plasma collection optimized for 
biomarker/proteomic/metabonomic anal ysis):A 2mL blood biospecimen will be 
collected at times specified in the Schedule of Activities section of the protocol. 
Prep B2.5(serum collection optimized for biomarker/proteomic/metabol omic 
analysis):a 2mL blood biospecimen will be collected at times specified in the 
Schedule of Activities section of the protocol. 
The banked biospecimens will be collected from all subjects unless prohibited by  local 
regulations or IRB/EC decision.
It is possible that the use of these biospecimens may  result in commercially viable products.  
Subjects will be advised in the informed consent document that they  will not be compensated 
in this event.
7.7.1. Additional Research
Unless prohibited by  local regulations or Institutional Review Board ( IRB)/Ethics Committee 
(EC)decision, subjec ts will be asked to indicate on the consent form whether they  will allow 
banked biospecimens to also be used to design and conduct research in order to gain a further 
understanding of other diseases and to advance science, including development of other 
medicines for patients.

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 68Subjects need not provide additional biospecimens for the uses described in this section; the 
biospecimens specified in the Banked Biospecimens section will be used.  Subjects may still 
participate in the study if they elect not to allow their banke d biospecimens to be used for the 
additional purposes described in this section.
 
 
 
 
 
8. ADVERSE EVENT REPORTING
8.1. Requirements
The table below summarizes the requirements for recording safet y events on the CRF and for 
reporting safety events on the Clinical Trial (CT) Serious Adve rse Event (SAE) Report Form 
to Pfizer Safety.  These requirements are delineated for 3 type s of events: (1) SAEs; 
(2) non-serious adverse events (AEs); and (3) exposure to the in vestigational product under 
study during pregnancy or breastfeeding, and occupational expos ure. 
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer Safety Within 24 Hours of Awareness
SAE All All
Non-serious AE All None
Exposure to the investigational product under study during pregnancy or breastfeeding, and occupational exposureAll (regardless of whether 
associated with an AE), 
except occupational 
exposureExposure during pregnancy, 
exposure via breastfeeding, occupational exposure (regardless of whether associated with an AE)
All observed or volunteered events regardless of treatment grou p or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragraphs.
Events listed in the table above that require reporting to Pfiz er Safety on the CT SAE Report 
Form within 24 hours of awareness of the event by the investigat orare to be reported 
regardless of whether the event is determined by the investigat or to be related to an 
investigational product under study .  In particular, if the SAE is fatal or life-threatening, 
notification to Pfizer Safety must be made immediately, irrespe ctive of the extent of available 
event information.  This time frame also applies to additional new (follow-up) information on 
previously forwarded reports.  In the rare situation that the i nvestigator does not become CCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 69immediately  aware of the occurrence of a n event, the investigator must report the event 
within 24 hours after learning of it and document the time of his/her first awareness of the 
event.
For each event, the investigator must pursue and obtain adequate information both to 
determine the outcome a nd to assess whether it meets the criteria for classification as an SAE 
(see the Serious Adverse Events section below).  In addition, the investigator may  be 
requested b y Pfizer Safety to obtain specific follow -up information in a n expedited fashion.  
This information is more detailed than that recorded on the CRF .  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and independent determination of po ssible causalit y.  An y information relevant to 
the event, such as concomitant medications and illnesses, must be provided.  I n the case of a 
subject death, a summary of available autopsy  findings must be submitted as soon as possible 
to Pfizer Safety .  An ypertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory  data) are to 
be sent to Pfizer Safet y ONLY upon request.
As part of ongoing safet y reviews conducted b y the spon sor, an y non -serious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE.  To assist 
in the determination of case seriousness, further information may  be requested from the 
investigator to provide clarity  and understanding of the event in the context of the clinical 
study .
8.1.1.
Additional Details On Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Report Form for r eporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on b oth the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneously  
reported b y the stud y subject.  In addition, each stud y subject will be questioned about the 
occurrence of AEs in a non -leading manner.
8.1.3. Withdrawal From the Study Due to Adverse Events (See also the Subject 
Withdrawal 6.5)
Withdrawal due to AEs should be distinguished from withdraw al due to other causes, 
according to the definition of AE noted below, and recorded on the CRF. 
When a subject withdraws from the study  because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in acco rdance with the 
Requirements section above.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 708.1.4. Time Period for Collecting AE/SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject provides informed co nsent, which 
is obtained before the subject’s participation in the study  (ie, before undergoing any  
study -related procedure and/or receiving investigational product), through and including a 
minimum of 28 calendar days after the last administration of the investigational product.
For subjects who are screen failures, the active collection period ends when screen failure 
status is determined.
8.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject during the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended are reported to Pfizer 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .
Follow up by  the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a le vel acceptable to the investigator, and 
Pfizer concurs with that assessment.
8.1.4.2. Recording Non -serious AEs and SAEs on the CRF
During the active collection period, both non-serious AEs and SAEs are recorded on the 
CRF.
Follow -up by  the investigator may  be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, and Pfizer concurs with that assessment.
8.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
non-serious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in accordance with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a re asonable 
possibility  that the investigational product caused or contributed to an AE; generall y the facts 
(evidence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational pro duct caused the event, then 
the event will be handled as “related to investigational product” for reporting purposes, as 
defined b y the sponsor.  If the investigator's causality
 assessment is “unknown but not 
related” to investigational product, this shoul d be clearl y documented on study  records. 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 71In addition, if the investigator determines that an SAE is associated with study  procedures, 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
inaccordance with applicable local regulations.
8.2.Definitions
8.2.1. Adverse Events
An AE is an y untoward medical occurrence in a study subject administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to: 
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in ph ysical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease
Drug abuse;
Drug dependency .
Additionally , AEs may  include signs and s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy  (EDP);
Exposure via breastfeeding;
Medication error;

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 72Occupational exposure.
8.2.2. Abnorma l Test Findings
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; and/or
Test result requires additional diagnostic testing or medical/surgical in tervention; 
and/or
Test result leads to a change in stud y dosing (outside of an y protocol -specified dose 
adjustments) or discontinuation from the study , significant additional concomitant 
drug treatment, or other therap y; and/or
Test result is considered t o be an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, in the absence of an y of the above conditions, does not 
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
A serious adverse event is any  untoward medical occurrence at any  dose that:
 Results in death;
 Is life -threatening (immediate risk of death);
 Requires inpatient hospitalization or prolongation of existing hospitalization;
 Results in persist ent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life functions);
 Results in congenital anomaly /birth defect.
Or that is considered to be:
An important medical event.
Medical and scientific judgment is exerc ised in determining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospitalization.  However, if it is determined that the event may  jeopardize 
the subject or ma y require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 73Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dy scrasias or convul sions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.
8.2.4. Hospitalization
Hospitalization is defined as an y initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility , or any  prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tuberculosis unit).  An em ergency  room visit does not necessarily constitute a hospitalization; 
however, the event leading to the emergency  room visit is assessed for medical importance.
Hospitalization does not include the following:
Rehabilitation facilities;
Hospice facilities;
Respite care (eg, caregiver relief);
Skilled nursing facilities;
Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
Hospitalization or prolongation of hospitalization in the absence of a precipitating clinical 
AE is not in it self an SAE.  Examples include:
Admission for treatment of a preexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory  abnormality );
Social admission (eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical examination);
Protocol -specified admission during a stud y (eg, for a procedure required by the stud y 
protocol);
Optional admission not associated with a preci pitating clinical AE (eg, for elective 
cosmetic surgery );
Hospitalization for observation without a medical AE;

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 74Preplanned treatments or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the indivi dual subject .
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE.  F or example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are met, and the resulting appendectomy  should be recorded as treatment of the 
AE.
8.3.Severity Assessment
If required on the AE page of the CRF, the investigator will use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum intensity  of the AE.  For purposes of 
consistency , these intensity  grades are defined as follows:
Severity  Assessment
MILD Does not interfere with subject's usual function.
MODERATE Interferes to some extent with subject's usual function.
SEVERE Interferes significantl y with subject's usual function.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SA E.  For example, a headache may  be severe (interferes significantly  with 
the subject's usual function) but would not be classified as serious unless it met one of the 
criteria for SAEs, listed above.
8.4.Special Situations
8.4.1. Protocol -Specified Serious Adverse Ev ents 
There are no protocol -specified SAEs in this study.  All SAEs will be reported to Pfizer 
Safety  by the investigator as described in previous sections, and will be handled as SAEs in 
the safet y database.
8.4.2. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a h arbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressive and serious liver injury , commonly  referred to as drug -induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
normal ( ×ULN) should be monitored more frequently  to determine if they are an “adaptor” 
or are “susceptible.”

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 75In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase ( ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  several 
days or weeks.  The increase in TBili ty picall y occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same lab sample).  
In rare instances, b y the time TBili elevations are detected, AST/ALT values might have 
decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR ALT in addition to TBili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the subject’s 
individual baseline values and underl ying conditions.  Subjects who present with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine th e etiology  of the abnormal laboratory  values:
Subjects with AST/AL T and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value 
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available;
For subjects with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexis
ting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller) ;
Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amo unt of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
r
epresents a potential Hy’s law case should be reviewed with the sponsor. 
The subject should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment. 
In addition to repeating measurements of AST and AL T and TBili, laboratory  tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutam yl 
transferase (GG T), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase and acetaminophen drug and/or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 76anticoagulate d tube of blood for further testing, as needed, for further contemporaneous 
analyses at the time of the recognized initial abnormalities to determine etiology .  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (e ither b y 
itself or as a coformulated product in prescription or over -the-counter medications) , 
recreational drug, supplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact with a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potential occupational exposure to chemicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg,biliary  tract) may  be warranted. 
All ca ses demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the liver function test ( LFT)abnormalities has y et been found.  Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability 
of all the results of the investigations performed to determine etiology of the LFT 
abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl
yafter all results of 
reasonable investigations have been received and have excluded an alternative etiology .
8.4.3. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.4.3.1. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
An example of environmental exposure would be a case involving direct contact 
with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to ch emotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed 
during his partner’s pregnancy .
If a subject or subject’s par tner becomes or is found to be pregnant during the subject’s 
treatment with the investigational product, the investigator must report this information to 
Pfizer Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 77whether an SAE has occurred.  In addition, the investigator must submit information 
regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a subject 
reports that she is pregnant and has been exposed to a cy totoxic product by inhalation or 
spillage) to Pfizer Safety  using the EDP supplemental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
inform ation related to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -
up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason (s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (unless 
pre-procedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal dem ise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion ;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  relat ed to 
exposure to the investigational product.
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmenta l delay s).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner Release of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the 
subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.4.3.2. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfizer 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 78accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
8.4.3.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, us ing the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a subject enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maint ained in the investigator site file.
8.4.4. Medication Errors 
Other exposures to the investigational product under study  may  occur in clinical trial settings, 
such as medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfize r 
Safety Within 24 Hours of 
Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an 
SAE
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subj ect, or at the wrong time, or at the wrong dosage strength .
Medication errors include :
Medication errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating subject.
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and non-serious, are recorded on an AE page of the 
CRF.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 79Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE .
9. DATA ANALYSIS/STATIS TICAL METHODS
Detailed methodology  for summary  and stat istical anal yses of the data collected in this study  
is outlined here and further detailed in a SAP , which will be maintained by  the sponsor.  The 
SAP may modify  what is outlined in the protocol where appropriate ; however, an y major 
modifications of the pr imary  endpoint definition s or their 
analyses will also be reflected in a 
protocol amendment.
9.1.Sample Size Determination
Approximately  98subjects will be randomized ina ratio of 1:2:2:2 to four treatment 
groups A:B:C:D, where A is the placebo group.
  Assum ing an approxim ate 14 % dropout rate 
this will ensure a minimum of 84 subjects complete the study .  This sample size (12 for the 
placebo group and 24 for the 
each of monotherap y groups and the combination group) is 
estimated to provide >90% power to detect a difference of 30% mean reduction in whole 
liver fat from MRI -PDFF relative to placebo for the PF -05221304 + PF -06865571 
combination using a 1-sided Ty peI error rate of 0.05.  This randomization schema will 
enable detection of a smaller effect of the com bo vs monotherapy  than of the monotherapies 
vs placebo.  Detecting a smaller effect requires a larger sample size and hence the sample 
size is increased for the active arms.   With the sample size of 24 completers for each of the 
active arms 
the power to de tect a pproximately  16% mean reduction in whole liver fat for the 
PF-
05221304 + PF-06865571 combination relative to each monotherap y is approximately  
90% using a 1-sided Ty peI error rate of 0.25.  These calculations assume a pooled standard 
deviation of th e log- relative change of 0.3 2(based on an internal study ). 
9.2.Analysis of the Primary Endpoint
The anal ysis population for primary  endpoint analy ses will include all randomized subjects 
who received at least 1 dose of IP (Full Analy sis set). 
The primary  endpoint will be the relative change from baseline to Day 42in whole liver 
PDFF.  Baseline will be the closest measurement prior to first dose on Day 1.  An anal ysis of 
covariance (ANCOVA) will be performed on log -transformed relative change from baseline 
with treatment and baseline diabetes as factors, and log -transformed baseline whole liver 
PDFF value as a covariate.  Estimates of the mean relative changes between placebo and 
each active drug arm (PF -05221304 monotherap y, PF-06865571 monotherapy  and 
PF-
05221304 plus PF -06865571 combination) at Day 42, and the corresponding 
90% confidence interval (CI) will be obtained from the model.  Similarly , PF-05221304 plus 
PF-06865571 combination will be compared to each monotherapy  through estimates of the 
mean rela tive change and corresponding 50% and 90% confidence intervals. No adjustment 
for multiple comparisons will be made.  If the model does not fit the data group medians and 
their differences from the placebo median will be presented.  The details will be pr ovided in 
the SAP.

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 80Descriptive summaries of the observed values and percent change  from baseline in whole 
liver PDFF for each treatment group will also be produced.
9.3. Analysis of Secondary Endpoints
Secondary endpoints relate to safety and tolerability whose anal yses are described in 
Section 9.7 .
9.4. Analysis of Tertiary/Exploratory Endpoints
Percent changes from baseline in LFTs will be summarized; group  medians and pairwise 
differences from the comparators will be presented.  Log-transf ormed relative changes from 
baseline in lipid panel parameters will be analyzed separately using mixed model for 
repeated measures (MMRM) with treatment, study day and interact ion of treatment with 
study day as factors, log-transformed baseline values of the de pendent variable, baseline 
diabetes status and log-transformed baseline whole liver PDFF a s covariates.   
 
  If the model does not fit the data model 
reduction techniques might be employed; otherwise, group median s and their differences 
from the placebo median will be presented.  Details will be pro vided in the SAP.
For all other pharmacodynamic endpoints/biomarkers to be include d in the CSR observed 
values, changes from baseline and/or percent changes from basel ine will be summarized 
descriptively at all collection time points.  Details and any a dditional analyses will be 
described in the SAP.
 
 
 
 
9.6. Analysis of Other Endpoints
Pharmacogenomic and biomarker data will be collected and retain ed for future analyses, but 
will not be analyzed for the purposes of CSR.
9.7. Safety Analysis
AEs, ECGs, BP, pulse rate, and safety laboratory data will be r eviewed and summarized on 
an ongoing basis during the study to evaluate the safety of sub jects.  Any clinical laboratory, 
ECG, BP, and pulse rate abnormalities of potential clinical conc ern will be described.  Safety 
data will be presented in tabular and/or graphical format and su mmarized descriptively, 
where appropriate. 
Physical examination information collected during the course of t he study will be considered 
source data and will not be required to be reported, unless othe rwise noted.  However, any CCICCI
PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 81untoward findings identified on physical examinations conducted  during the active collection 
period will be captured as AEs, if those findings meet the defin ition of an AE. 
Data collected at screening that are used for inclusion/exclusio n criteria, such as laboratory 
data, ECGs, and vital signs, will be considered source data, and will not be required to be 
reported, unless otherwise noted.  Demographic data collected a t screening will be reported. 
Vital Signs Analysis
Changes from baseline in systolic blood pressure, diastolic blo od pressure and pulse rate will 
be summarized by treatment and time.  The number (%) of subject s with maximum increases 
from baseline will be tabulated by treatment as defined in the SAP.  Numbers and 
percentages of subjects meeting the categorical criteria will b e provided and individual 
values listed in the study report.  No formal inferential stati stics will be applied to the vital 
signs data.
Electrocardiogram Analysis 
Changes from baseline for the ECG parameters QT interval, heart  rate, QTcF interval, PR 
interval, and QRS interval will be summarized by treatment and t ime.  QTcF will be derived 
using Fridericia’s heart rate correction formula.  The number ( %) of subjects with maximum 
increases from baseline will be tabulated by treatment as define d in the SAP.  Numbers and 
percentages of subjects meeting the categorical criteria will b e provided and individual 
values listed in the study report.  No formal inferential stati stics will be applied to the ECG 
data.
9.8. Interim Analysis
If, after randomization of approximately 50% subjects of planned  number of subjects, a 
monthly safety review reveals that the study meets one or more criteria listed in Section 3.3 , 
an interim analysis will be performed in an un-blinded manner b y a pre-specified IRC, 
independent from study team.  
 
Before any interim analysis is initiated, the details of the ob jectives, decision criteria, 
dissemination plan, and method of maintaining the study blind a s per Pfizer’s SOPs will be 
documented and approved in an IRC charter.  The analysis details will be documented and 
approved in an interim analysis SAP or final SAP.
9.9. Data Monitoring Committee 
This study will not use a data monitoring committee.CCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 8210.QUALITY CONTROL AND QUALITY ASSURANCE
Pfizer or its agent will conduct periodic monitoring visits during stud y conduct to ensure that 
the protocol and Good Clinical Practices ( GCPs) are being followed.  The monitors may  
review source documents to confirm that the data recorded on CRFs areaccurate.  The 
investigator and institution will allow Pfizer monitors /auditors or its agents and appropriate 
regulatory  authorities direct access to source documents to perform this verification.   This 
verification may  also occur after study  completion.
During stud y conduc t and/or after stud y completion, t he investigator 
site may  be subject to 
review b y the IRB/EC , and/or to quality  assurance audits performed by  Pfizer, or companies 
working with or on behalf of Pfizer, and/or to inspection by  appropriate regulatory  
authorit ies.
The investigator(s) will notify  Pfizer or its agents immediately  of any  regulatory  inspection 
notification in relation to the study . Furthermore, the investigator will cooperate with Pfizer 
or its agents to prepare the investigator site for the inspe ction and will allow Pfizer or its 
agent, whenever feasible, to be present during the inspection.  The investigator site and 
investigator will promptly resolve an y discrepancies that are identified between the stud y 
data and the subject's medical records. 
The investigator will promptl y provide copies of the 
inspection findings to Pfizer or its agent.  Before response submission to the regulatory 
authorities, the investigator will provide Pfizer or its agents with an opportunity  to review 
and comment on responses to any  such findings.
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
11.DATA HANDLING AND RE CORD KE EPING
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this study .
A CRF is required and should be completed for each included subject.  The completed 
original CRFs are the sole propert y of Pfizer and should not be made available in any form to 
third parties, except for authorized representatives of Pfizer or appropriate regulatory  
authorit ies, without written permission from Pfizer.  The investigator shall ensure that the 
CRFs are securel y stored at the study  site in encrypted electronic and/or paper form and will 
be password protected or secured in a locked room to prevent access b y unauth orized third 
parties.
The investigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y
,and laboratory  data entered on the CRFs and any  other data collection forms (source 
documents) and ensuring th at they  are accurate, authentic /original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring ,and available when required.  The 
CRFs must be signed b y the investigator or b y an authorized staff member to attest that the 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 83data contained on the CRFs aretrue. Any correcti ons to entries made in the CRFs or source 
documents must be dated, initialed ,and explained (if necessary ) and should not obscure the 
original entry . 
In most cases, the source documents are the hospital or the ph ysician subject chart.  In these 
cases , data collected on the CRFs must match the data in those charts. 
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigator site and at Pfizer that clearl y identifies those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document.
11.2. Record Retention
To enable evaluations and/or 
inspections/ audits from regulatory  authorities or Pfizer, the 
investigator agrees to keep records, includin g the identity  of all participating subjects 
(sufficient information to link records, eg, CRFs and hospital records), all original signed 
informed consent documents, copies of all CRFs, safet y reporting forms, source documents, 
and detailed records of trea tment disposition, and adequate documentation of relevant 
correspondence ( eg, letters, meeting minutes, and telephone call reports).  The records should 
be retained b y the investigator according to the ICH guidelines, according to local 
regulations, or as specified in the clinical study agreement (CSA) , whichever is longer. The 
investigator must ensure that the records continue to be stored securel y for so long as they are 
retained.
If the investigator becomes unable for an y reason to continue to retain st
udy records for the 
required period ( eg, retirement, relocation), Pfizer should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to Pfizer , such as another 
investigator, another institution, or an independent third party  arranged by  Pfizer. 
Investigator records must be kept for a minimum of 15 years after completion or 
discontinuation of the study or for longer if required by  applicable local regulations.
The investigator must obtain Pfizer's written permission b efore disposing of an y records, 
even if retention requirements have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent documents, and other relevant documents, eg,
recruitment advertisements, if applicable, from the I RB/EC.  All correspondence with the
IRB/EC should be retained in the investigator f ile.  Copies of IRB/EC approvals should be 
forwarded to Pfizer.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 84Theonly circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and Pfizer in writing immed iately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, legal and regulatory  
requirements, and the general principles set forth in the I nternational Ethical Guidelines for 
Biomedical Resear ch Involving Human Subjects (Council for International Organizations of 
Medical Sciences 2002), ICH Guideline for G ood Clinical Practice , and the Declaration of 
Helsinki .
12.3. Subject Information and Consent
All parties will comply  with all applicable laws, inc luding laws regarding the implementation 
of organizational and technical measures to ensure protection of subject personal data
.  Such 
measures will 
include omitting subject names or other directl y identifiable data in an y
reports, publications, or other disclosures, except where required b y applicable law.
The personal data will be stored at the study  site in encry pted electronic and/or paper form 
and will be password protected or secured in a locked room to ensure that only  authorized 
study  staff have ac cess.  The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site shall be responsible 
for de termining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  law.
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, w hen study  data arecompiled for transfer to Pfizer and other authorized 
parties, s ubject name swill be removed and will be replaced by  a single, specific, numerical 
code based on a numbering s ystem 
defined by Pfizer .All other identifiable data transferred 
to Pfizer or other authori zed parties will be identified by  this single, subject- specific code.  
The investigator site will maintain a confidential list of subjects who participated in the 
study ,linking each subject’s numerical code to his or her actual identity .  In case of data 
transfer, Pfizer will maintain high standards of confidentiality  and protection of subject s’
personal data consistent with the Clinical Study  Agreement and applicable privacy  laws .
The informed consent document sand an y subject recruitment materials must b e in 
compliance with ICH GCP, local regulatory  requirements, and legal requirements, including 
applicable privacy  laws .
The informed consent document s used during the informed consent process and an y subject 
recruitment materials 
must be reviewed and appro ved by Pfizer , approved by  the IRB/EC
before use , and available for inspection.
The investigator must ensure that each study  subject is fully  informed about the nature and 
objectives of the stud y, the sharing of data relating to the stud yand possible risk
s associated 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 85with participation , including the risks associated with the processing of the subject’s personal 
data.  The investigator further must ensure that each study  subject is fully  informed about his 
or her right to access and correct his or her pers onal data and to withdraw consent for the 
processing of his or her personal data . 
The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each subject before any  study -specific activity  is performe d. The in vestigator 
will retain the original of each subject's signed consent document .
12.4. Reporting of Safety Issues and S erious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory authorit y in any area of the world, or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer should be informed immediately. 
In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
13.DEFINITION OF END OF TRIAL
13.1. End of Trial in A llParticipating Countries 
End of trial in all participating countries is defined as l ast subject last visit (LSLV) –the date 
the investigator reviews the last subject’s final safety  data and determines that no further 
evaluation is required for the subjects to complete the trial.
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opinion of the IRB/EC , orinvestigational product safety  prob lems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue development of one or 
both I Ps (PF-05221304 and PF -06865571) 
at an y time.
If a stud y is prematurel y terminated, Pfizer will promptly  notify  the investigator.  After
notification, the investigator must contact all participating subjects and the hospital pharmacy  
(if applicable) within 7 days.  As directed b y Pfizer, all study materials must be collected and 
all CRFs completed to the greatest extent possible.
15.PUBLICATI ON OF STUDY RESULTS
15.1. Communication of Results by Pfizer
Pfizer fulfills its commitment to publicly  disclose clinical trial results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database ( EudraCT), and/ or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations. 

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 86In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of t he outcome of the study  or the country  in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer- sponsored 
interventional studies (conducted in patients) that evaluate the saf ety and/or efficacy of a 
Pfizer product , regardless of the geographical location in which the study is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary completion date (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final subject was examined or received an intervention for 
the purposes of final collection of data for the primary  outcome, whether the clinical study  
concluded according to the pre specified protocol or was terminated.
EudraCT
Pfizer posts European Union ( EU)Basic Results on EudraCT for all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts Public Disclosure Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify  individual patients has been removed) on www.pfizer.com for 
Pfizer -
sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov .
15.2. Publications by Investigators
Pfizer supports the exercise of academic f reedom and has no objection to publication by  the 
principal investigator (PI) of the results of the study based on information collected or 
generated b y the 
PI, whether or not the results are favorable to the Pfizer product.  However, 
to ensure aga inst ina dvertent disclosure of confidential i nformation or unprotected 
inventions, 
the investigator will provide Pfizer an opportunity  to review any  proposed 
publication or other t ype of disclosure of the results of the s tudy (collectively , “publication”) 
before i t is submitted or otherwise disclosed.
The i nvestigator will provide any publication to Pfizer at least 30 days before 
it is submitted 
for publication or otherwise disclosed. If any patent action is required to protect intellectual 
propert y rights, the investigator agrees to delay  the disclosure for a period not to exceed an 
additional 60 days.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 87The i nvestigator will, on request, remove an y previously  undisclosed confidential 
information bef ore disclosure, except for any  study-or Pfizer product -related inf ormation 
necessary  to the appropriate scientific presen tation or understanding of the s tudy results.
If the study  is part of a multi centerstudy , the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that an y subsequent 
publications 
bythe PI will reference that primary  publication . However, if a joint manuscript has not 
been submitted for publication within 12 months of completion or termination of the s tudy at 
all participating sites, the investigator is free to publish separatel y, subject to the other 
requirements of this s ection.
For all publications relating to the study, the i nstitution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  the International Committee of Medical Journal E
ditors.
Publication of study  results is also provided for in the CSA between Pfizer and the 
institution.  I n this section entitled Publications by  Investigators, the defined terms shall have 
the meanings given to them in the CSA.
If there is an y conflict between the CSA and an y attachments to it, the terms of the CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of s tudy subjects, and the CSA wil l control as to all other 
issues.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 8816.REFERENCES
1. Savage DB, Choi CS, Samuel VT, et al. Reversal of diet -induced hepatic steatosis and 
hepatic insulin resistance by  antisense oligonucleotide inhibitors of acet yl-CoA 
carbox ylases 1 and 2. J Clinical I nvest2006; 116(3):817-24.
2. Kim CW, Addy  C, Kusunoki J, et al. Acety l CoA carboxy lase inhibition reduces hepatic 
steatosis but elevates plasma trigl ycerides in mice and humans: a bedside to bench 
investigation. Cell Metab 2017; 26(3):576. 
3. Berod L, Friedrich C, Nandan A, et al. De novo fatty  acid s ynthesis controls the fate 
between regulatory  T and T helper 17 cells. Nat Med 2014; 20(11):1327–33.
4. Yen CL , Stone SJ, Koliwad S, et al.  Thematic review series: gl ycerolipids. DGAT 
enzy mes and triacy lglycerol biosy nthesis.  J Lipid Res 2008;49(11):2283- 301.
5.
Buhman KK, Smith SJ, Stone SJ, et al.  DGAT1 is not essential for intestinal 
triacy lglycerol absorption or chy lomicron sy nthesis.  J Biol Chem 2002;277(28):25474 -
9.
6. Cases S, Stone SJ, Zhou P, et al.  Cloning of DGAT2, a sec ond mammalian 
diacy lglycerol acy ltransferase, and related family  members.  J Biol Chem 
2001;276(42):38870-6.
7. Choi CS, Savage DB. Suppression of diacy lglycerol acy ltransferase -2 (DGAT2), but 
not DGAT1, with antisense oligonucleotides reverses diet- induced hepatic steatosis and 
insulin resistance. J Biol Chem 2007;282(31):22678-88.
8. Yu XX, Murray  SF, Pandey  SK, et al.  Antisense oligonucleotide reduction of DGAT2 
expression improves hepatic steatosis and h yperlipidemia in obese mice.  Hepatology 
2005;42(2):362 -71.
9. Liu Y, Millar JS, Cromley  DA, et al.  Knockdown of acy l-CoA:diacy lglycerol 
acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion 
in mice.  Biochim Biophys Acta 2008;1781(3):97 -104.
10. L aBrecque D, Abbas Z, Anania F, et al. N onalcoholic fatty  liver disease and 
nonalcoholic steatohepatitis. I n: WGO Global Guidelines NAFLD/NASH (long 
version). Milwaukee, WI: World Gastroenterology  Organisation; 2012: 29 pages.
11. Sany al AJ, Friedman SL , McCullough AJ, et al. Challenges and opportun ities in drug 
and biomarker development for nonalcoholic steatohepatitis: findings and 
recommendations from an American Association for the Study  of L iver Diseases -U.S. 
Food and Drug Administration Joint Workshop.  Hepatology 2015; 61(4):1392-405.
12. Khan F, Perumpail R, Wong R, et al. Advances in hepatocellular carcinoma: 
Nonalcoholic steatohepatitis -related hepatocellular carcinoma. World J Hepatol 
2015; 7(18):2155-61.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 8913. Younossi Z, Koenig A, Abdelatif D, et al. Global epidemiology  of nonalcoholic fatty  
liver disease –meta -analy tic assessment of prevalence, incidence, and outcomes.  
Hepatology  2016;64(1):73-84.
14. Noureddin M, Anstee Q, Loomba R.  Review article: emerging anti-fibrotic therapies in 
the treatment of non -alcoholic steatohepatitis.  Aliment Pharmac ol Ther 
2016;43(11):1109 -23.
15. Lambert JE, Ramos -Roman MA, Browning JD, et al. Increased de novo lipogenesis is a 
distinct characteristic of individuals with nonalcoholic fatty  liver disease. 
Gastroenterology  2014; 146(3):726-35.
16. Motohashi H, I nui K. Organic cation transporter OCTs (SL C22) and MATEs (SL C47) 
in human kidney . AAPS J 2013; 15(2):581 -8.

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 90Appendix 1.Abbreviations 
This following is a list of abbreviations that may  be used in the protocol. 
Abbreviation Term
A1AT α-1-antitry psin
Abs absolute
ACC1/2 acetyl-CoA (coenzy me A) carboxy lase 1 and 2
ACCi acetyl-CoA (coenzy me A) carboxy lase inhibitor
ADR adverse drug reaction
AE adverse event
ALT alanine aminotransferase
ANCOVA analysis of covariance
AST aspartate a minotransferase
AUC area under the curve
BBS biospecimen banking s ystem
BCRP breast cancer resistance protein
BE bioequivalence
BID twice dail y
BMI body  mass index
BP blood pressure
Bpm beats per minute
BUN blood urea nitrogen
CAP controlled atte nuation parameter
CDK -Epi Chronic Kidney  Disease Epidemiology  Collaboration
Ceff efficacious concentration 
CFB change from baseline
CI confidence interval
CK creatine kinase
CLr renal clearance
Cmax maximum observed concentration
Cmin minimum conc entration
CNS central nervous s ystem
CO2 carbon dioxide (bicarbonate)
CoA coenzy me A
CRF case report form
CRU clinical research unit
CSA clinical study  agreement
CSF cerebrospinal fluid
CSR clinical study  report
CT clinical trial
CTA clinical trial application
CTCAE common terminology  criteria for a dverse e vents
CV coefficient of variation

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 91Abbreviation Term
CYP450 cytochrome P450
DAG diacy lglycerol
dB/m decibels per meter
DDI drug-drug interaction
DGAT diacy lglycerol acy ltransferase
DILI drug-induced liver injury
DMC data monitoring committee
DNA deox yribonucleic acid
DNL de novo lipogenesis
DPP-4 dipeptidy l peptidase-4
DPP-IVi dipeptidy l peptidase-IV inhibitors
DU dispensable unit
EC ethics committee
ECG electrocardiogram
E-DMC external data monito ring committee 
EDP exposure during pregnancy
EDR extemporaneous dispensing record
EDTA edetic acid (eth ylenediaminetetraacetic acid)
EFD embry o-fetal development
eGFR estimated glomerular filtration rate
EU European Union
EudraCT European Clinical Trials Database
FA fatty acids
FFA free fatt y acids
FPG fasting plasma glucose
FSH follicle -stimulating hormone
GCP good clinical practice
GFR glomerular filtration rate
GGT gamma -glutamy l transferase
GLDH glutamate deh ydrogenase
GLP good laboratory  practice
GLP-1r glucagon-like peptide- 1 receptor
hr. hour(s)
HbA1c hemoglobin A1c
HBV hepatitis B virus
HCC hepatocellular carcinoma
hCG human chorionic gonadotropin
HCV hepatitis C virus
HepBcAb hepatitis B core antibod y
HepBsAg hepatitis B surface antigen
HCVAb hepatitis C antibody
HDL -C high densit y lipoprotein cholesterol

PF-05221304 and PF-06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 92Abbreviation Term
HIV human immunodeficiency virus
IA interim analysis
IB investigator’s brochure
ICD informed consent document
ICH International Conference on Harmonisation
ID identification
IND investigational new drug
INR international normalized ratio
IP investigational product 
IR immediate release
IRB institutional review board
IRC internal review committee
IRT interactive response technology
IUD intrauterine device
IV intravenous
K2EDTA dipotassium ethylenediaminetetraacetic acid
kPa kilopascal
LDL-C low density lipoprotein cholesterol
LFT liver function test
LLN lower limit of normal
LSLV last subject last visit 
LSM liver stiffness measure
MATE multi-drug and toxin extrusion protein
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MDR1 multi-drug resistance protein 1
MDRD modification of diet in renal disease equation
MELD model of end-stage liver disease
MIST metabolites in safety testing
MK megakaryocytes
MMRM mixed model for repeated measures 
MR modified release
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
MTD maximum tolerated dose
N/A not applicable
NAFLD non-alcoholic fatty liver disease
NASH non-alcoholic steatohepatitis
NMN N-methylnicotinamideCCI
CCI
PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 93Abbreviation Term
NOAEL no observed adverse effect level
NSAIDs non-steroidal anti -inflammatory  medications
NYHA New York Heart Association
OAT organic anion transporter
OATP organic anion transporter poly peptide
OCT organic cation transporter
PCD primary  completion date
PCSK9 proprotein convertase subtilisin/kexin ty pe 9
PD pharmaco dynamic(s)
PDFF proton density  fat fraction
P-gp P-glycoprotein
pH potential of hy drogen
PGx pharmacogenomic
PI principal investigator
PK pharmacokinetic(s)
PT prothrombin time
PTR peak to trough ratio
Q8hr. every  8 hours
Q12hr every  12 hours
QD quodque die (once dail y)
QTc corrected QT interval
qual qualitative
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analy sis plan
SCr serum creatinine
Scys serum cy statin
SD standard deviation
SGL T2 sodium -gluco se co -transporter 2
SOC system organ class
SOP standard operating procedure
SRSD single reference safet y document
t1/2 half-life
SSID single subject identifier
TBili total bilirubin
T2DM type 2 diabetes mellitus
TEAE treatment emergent adverse even t
TG triglycerides
Th17 T-helper 17 lineage
Tmax time to reach maximum concentration
Treg regulatory T

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 94Abbreviation Term
TZD thiazolidinediones
ULN upper limit of normal
US United States
VCTE vibration controlled transient elastograph y
VLDL very low densit y lipopr otein
WBC white blood cell

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 95Appendix 2.Strong CYP3A Inhibitors and Inducers *
CYP 3A Inhibitors CYP 3A Inducers
HIV antivirals HIV antivirals
Indinavir Nevirapine
Nelfinavir Miscellaneous
Ritonavir Barbiturates
Saquinavir Carbamazepine
Boceprevir Glucocortico ids (systemic)
Lopinavir/ritonavir Oxcarbazepine
Amprenavir Phenobarbital
Atazanavir Phenytoin
Telaprevir Rifabutin
Darunavir/ritonavir Rifampin
Fosamprenavir St. John's wort2
Tiprinavir/ritonavir Troglitazone
Antibiotics Nafcillin
Clarithromycin Avasimibe3
Troleandomycin Enzalutamide
Telithromycin Mitotane
Anti -infectives
Itraconazole
Ketoconazole
Posaconazole
Voriconazole
Miscellaneous
Nefazodone
Grapefruit juice1
Conivaptan
Idelalisib
1. Subjects will not be allowed to eat o r drink grapefruit or grapefruit -related citrus fruits (eg, Seville oranges, 
pomelos).
2. The effect of St. John’s wort varies widely and is preparation -dependent.
3. Not a marketed drug.
* This list is not considered as exhaustive.  Any questions regarding use of CYP3A inhibitors and inducers should be 
directed to the Sponsor study team.
Reference: U.S. Food and Drug Administration.  Drug Development and Drug Interactions: Table of Substrates, 
Inhibitors and Inducers, available at : 
https://www.fda.gov/Drugs/De velopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm09366
4.htm

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 96Appendix 3. Guidance to Investigators –Management of Individual Subjects With 
Decrease in Platelet Count

PF-05221304 and PF -06865571
C3711001
Final Protocol Amendment 1, 02 October 2018
Page 97Appendix 4. Guidance to Investigators –Management of Individual Subjects With 
Elevation in Fasting Serum Triglycerides
